studyID,icerID,uniqueID,firstAuthor,pubYear,title,country,income,asiaPacific,intervention,comparator,comparison,doseNum,baseCase,perspective,currencyName,currencyCountry,priceYear,priceIntvNCU,priceIntvUSD,priceCompNCU,priceCompUSD,herdEffects,seroReplace,efficacyPneum,efficacyIPD,efficacyOtitis,icerMetric,icerNCU,icerUSD,costSaving,gdppc,gdp1decide,gdp3decide,icerGdppc,OHgdppc,OHdecide,OLgdppc,OLdecide,WHgdppc,WHdecide,WLgdppc,WLdecide,RHgdppc,RHdecide,RLgdppc,RLdecide,studyThreshold,studyDecide,switchOH,switchOL,switchWH,switchWL,switchRH,switchRL,switches,budgetImpact,funding
1,1,101,Che,2014,Modeling the impact of the 7-valent pneumococcal conjugate v,China,Upper-middle,1,PCV7,NoVax,PCV7 vs NoVax,Three,1,Societal,US dollar,United States,2011,127,127,,,0,0,1,1,1,QALY gained,530354,530354,0,5614,Not cost-effective,Not cost-effective,94.46,0.71,Not cost-effective,0.45,Not cost-effective,0.648116898,Not cost-effective,0.163952209,Not cost-effective,0.902715505,Not cost-effective,0.374118744,Not cost-effective,One/Three GPDpc,Not cost-effective,,,,,,,0,0,Non-profit
1,2,102,Che,2014,Modeling the impact of the 7-valent pneumococcal conjugate v,China,Upper-middle,1,PCV7,NoVax,PCV7 vs NoVax,Three,0,Societal,US dollar,United States,2011,127,127,,,1,0,1,1,1,QALY gained,95319,95319,0,5614,Not cost-effective,Not cost-effective,16.98,0.71,Not cost-effective,0.45,Not cost-effective,0.648116898,Not cost-effective,0.163952209,Not cost-effective,0.902715505,Not cost-effective,0.374118744,Not cost-effective,One/Three GPDpc,Not cost-effective,,,,,,,0,0,Non-profit
2,1,201,Caldwell,2015,The health and economic impact of vaccination with 7-valent ,China,Upper-middle,1,PCV7,NoVax,PCV7 vs NoVax,Four,1,Healthcare/payer,Chinese yuan,China,2011,860,133.1,,,1,0,1,1,1,QALY gained,13737,2206,0,5614,Cost-effective,Cost-effective,0.39,0.71,Cost-effective,0.45,Cost-effective,0.648116898,Cost-effective,0.163952209,Not cost-effective,0.902715505,Cost-effective,0.374118744,Not cost-effective,Three GDPpc,Cost-effective,0,0,0,1,0,1,2,0,Industry
3,1,301,Maurer,2016,Cost-effectiveness analysis of pneumococcal vaccination for ,China,Upper-middle,1,PCV7,NoVax,PCV7 vs NoVax,Unknown,1,Societal,US dollar,United States,2014,146,146,,,0,0,1,1,1,QALY gained,18224,18224,0,7636,Not cost-effective,Cost-effective,2.39,0.71,Not cost-effective,0.45,Not cost-effective,0.648116898,Not cost-effective,0.163952209,Not cost-effective,0.902715505,Not cost-effective,0.374118744,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Non-profit
3,2,302,Maurer,2016,Cost-effectiveness analysis of pneumococcal vaccination for ,China,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Unknown,1,Societal,US dollar,United States,2014,146,146,,,0,0,1,1,1,QALY gained,16664,16664,0,7636,Not cost-effective,Cost-effective,2.18,0.71,Not cost-effective,0.45,Not cost-effective,0.648116898,Not cost-effective,0.163952209,Not cost-effective,0.902715505,Not cost-effective,0.374118744,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Non-profit
3,3,303,Maurer,2016,Cost-effectiveness analysis of pneumococcal vaccination for ,China,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Unknown,1,Societal,US dollar,United States,2014,146,146,,,0,0,1,1,1,QALY gained,11436,11436,0,7636,Not cost-effective,Cost-effective,1.5,0.71,Not cost-effective,0.45,Not cost-effective,0.648116898,Not cost-effective,0.163952209,Not cost-effective,0.902715505,Not cost-effective,0.374118744,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Non-profit
4,1,401,Mo,2016,Cost-effectiveness and health benefits of pediatric 23-valen,China,Upper-middle,1,PCV7,NoVax,PCV7 vs NoVax,Four,1,Societal,US dollar,United States,2015,58,58,,,1,0,1,1,1,QALY gained,104094,104094,0,8016,Not cost-effective,Not cost-effective,12.99,0.71,Not cost-effective,0.45,Not cost-effective,0.648116898,Not cost-effective,0.163952209,Not cost-effective,0.902715505,Not cost-effective,0.374118744,Not cost-effective,Three GDPpc,Not cost-effective,,,,,,,0,0,None
4,2,402,Mo,2016,Cost-effectiveness and health benefits of pediatric 23-valen,China,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Four,1,Societal,US dollar,United States,2015,58,58,,,1,0,1,1,1,QALY gained,29460,29460,0,8016,Not cost-effective,Not cost-effective,3.67,0.71,Not cost-effective,0.45,Not cost-effective,0.648116898,Not cost-effective,0.163952209,Not cost-effective,0.902715505,Not cost-effective,0.374118744,Not cost-effective,Three GDPpc,Not cost-effective,,,,,,,0,0,None
5,1,501,Shen,2018,Estimating the cost-effectiveness of an infant 13-valent pne,China,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Four,1,Healthcare/payer,Chinese yuan,China,2015,698,112.1,,,0,0,1,1,1,QALY gained,79304,12735,0,8016,Not cost-effective,Cost-effective,1.59,0.71,Not cost-effective,0.45,Not cost-effective,0.648116898,Not cost-effective,0.163952209,Not cost-effective,0.902715505,Not cost-effective,0.374118744,Not cost-effective,Two GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Industry
5,2,502,Shen,2018,Estimating the cost-effectiveness of an infant 13-valent pne,China,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Four,1,Healthcare/payer,Chinese yuan,China,2015,698,112.1,,,1,0,1,1,1,QALY gained,76551,12292,0,8016,Not cost-effective,Cost-effective,1.53,0.71,Not cost-effective,0.45,Not cost-effective,0.648116898,Not cost-effective,0.163952209,Not cost-effective,0.902715505,Not cost-effective,0.374118744,Not cost-effective,Two GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Industry
5,3,503,Shen,2018,Estimating the cost-effectiveness of an infant 13-valent pne,China,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Four,1,Healthcare/payer,Chinese yuan,China,2015,698,112.1,,,1,0,1,1,1,QALY gained,3777,607,0,8016,Cost-effective,Cost-effective,0.08,0.71,Cost-effective,0.45,Cost-effective,0.648116898,Cost-effective,0.163952209,Cost-effective,0.902715505,Cost-effective,0.374118744,Cost-effective,Two GDPpc,Cost-effective,0,0,0,0,0,0,0,0,Industry
6,1,601,Zhou,2018,Cost-effectiveness analysis of routine 13-valent pneumococca,China,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Four,0,Healthcare/payer,US dollar,United States,2016,138.7,138.7,,,0,1,1,1,1,QALY gained,20709,20709,0,8094,Not cost-effective,Cost-effective,2.56,0.71,Not cost-effective,0.45,Not cost-effective,0.648116898,Not cost-effective,0.163952209,Not cost-effective,0.902715505,Not cost-effective,0.374118744,Not cost-effective,One GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Government
6,2,602,Zhou,2018,Cost-effectiveness analysis of routine 13-valent pneumococca,China,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Four,1,Societal,US dollar,United States,2016,138.7,138.7,,,0,1,1,1,1,QALY gained,18483,18483,0,8094,Not cost-effective,Cost-effective,2.28,0.71,Not cost-effective,0.45,Not cost-effective,0.648116898,Not cost-effective,0.163952209,Not cost-effective,0.902715505,Not cost-effective,0.374118744,Not cost-effective,One GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Government
7,1,701,Aljunid,2011,Impact of routine PCV7 (Prevenar) vaccination of infants on ,Malaysia,Upper-middle,1,PCV7,NoVax,PCV7 vs NoVax,Four,1,Healthcare/payer,Malaysian ringgit,Malaysia,2007,222,64.6,,,1,0,1,1,1,QALY gained,35196,10239,0,7243,Not cost-effective,Cost-effective,1.41,0.75,Not cost-effective,0.45,Not cost-effective,0.564443129,Not cost-effective,0.317316947,Not cost-effective,0.668688739,Not cost-effective,0.277184384,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Industry
8,1,801,Aljunid,2014,Economic impact of pneumococcal protein-D conjugate vaccine ,Malaysia,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2010,,,,,1,0,1,1,1,QALY gained,9406,9046,0,9041,Not cost-effective,Cost-effective,1,0.75,Not cost-effective,0.45,Not cost-effective,0.564443129,Not cost-effective,0.317316947,Not cost-effective,0.668688739,Not cost-effective,0.277184384,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Industry
8,2,802,Aljunid,2014,Economic impact of pneumococcal protein-D conjugate vaccine ,Malaysia,Upper-middle,1,PCV13,PCV10,PCV13 vs PCV10,Four,1,Healthcare/payer,US dollar,United States,2010,,,,,1,0,1,1,1,QALY gained,61061,61061,0,9041,Not cost-effective,Not cost-effective,6.75,0.75,Not cost-effective,0.45,Not cost-effective,0.564443129,Not cost-effective,0.317316947,Not cost-effective,0.668688739,Not cost-effective,0.277184384,Not cost-effective,Three GDPpc,Not cost-effective,,,,,,,0,0,Industry
9,1,901,Wang,2017,Cost-effectiveness analysis of a universal mass vaccination ,Malaysia,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2014,34.3,34.3,,,0,0,1,1,1,QALY gained,28497,28497,0,11319,Not cost-effective,Cost-effective,2.52,0.75,Not cost-effective,0.45,Not cost-effective,0.564443129,Not cost-effective,0.317316947,Not cost-effective,0.668688739,Not cost-effective,0.277184384,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Industry
9,2,902,Wang,2017,Cost-effectiveness analysis of a universal mass vaccination ,Malaysia,Upper-middle,1,PCV13,PCV10,PCV13 vs PCV10,Three,0,Healthcare/payer,US dollar,United States,2014,34.3,34.3,34.25,34.3,0,0,1,1,1,QALY gained,44908,44908,0,11319,Not cost-effective,Not cost-effective,3.97,0.75,Not cost-effective,0.45,Not cost-effective,0.564443129,Not cost-effective,0.317316947,Not cost-effective,0.668688739,Not cost-effective,0.277184384,Not cost-effective,Three GDPpc,Not cost-effective,,,,,,,0,0,Industry
10,1,1001,Wu,2016,Cost-effectiveness analysis of infant universal routine pneu,Malaysia,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2014,55,55,,,1,0,1,1,1,QALY gained,21438,21438,0,11319,Not cost-effective,Cost-effective,1.89,0.75,Not cost-effective,0.45,Not cost-effective,0.564443129,Not cost-effective,0.317316947,Not cost-effective,0.668688739,Not cost-effective,0.277184384,Not cost-effective,One GDPpc,Not cost-effective,,,,,,,0,0,Industry
10,2,1002,Wu,2016,Cost-effectiveness analysis of infant universal routine pneu,Malaysia,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Four,1,Societal,US dollar,United States,2014,55,55,,,1,0,1,1,1,QALY gained,20667,20667,0,11319,Not cost-effective,Cost-effective,1.83,0.75,Not cost-effective,0.45,Not cost-effective,0.564443129,Not cost-effective,0.317316947,Not cost-effective,0.668688739,Not cost-effective,0.277184384,Not cost-effective,One GDPpc,Not cost-effective,,,,,,,0,0,Industry
10,3,1003,Wu,2016,Cost-effectiveness analysis of infant universal routine pneu,Malaysia,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2014,55,55,,,1,0,1,1,1,QALY gained,6389,6389,0,11319,Cost-effective,Cost-effective,0.56,0.75,Cost-effective,0.45,Not cost-effective,0.564443129,Not cost-effective,0.317316947,Not cost-effective,0.668688739,Cost-effective,0.277184384,Not cost-effective,One GDPpc,Cost-effective,0,1,1,1,0,1,4,0,Industry
10,4,1004,Wu,2016,Cost-effectiveness analysis of infant universal routine pneu,Malaysia,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Four,1,Societal,US dollar,United States,2014,55,55,,,1,0,1,1,1,QALY gained,4883,4883,0,11319,Cost-effective,Cost-effective,0.43,0.75,Cost-effective,0.45,Cost-effective,0.564443129,Cost-effective,0.317316947,Not cost-effective,0.668688739,Cost-effective,0.277184384,Not cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,1,2,0,Industry
10,5,1005,Wu,2016,Cost-effectiveness analysis of infant universal routine pneu,Malaysia,Upper-middle,1,PCV13,PCV10,PCV13 vs PCV10,Four,1,Healthcare/payer,US dollar,United States,2014,55,55,55,55,1,0,1,1,1,QALY gained,-3059,-3059,1,11319,Cost-saving,Cost-saving,-0.27,0.75,Cost-saving,0.45,Cost-saving,0.564443129,Cost-saving,0.317316947,Cost-saving,0.668688739,Cost-saving,0.277184384,Cost-saving,One GDPpc,Cost-saving,,,,,,,0,0,Industry
10,6,1006,Wu,2016,Cost-effectiveness analysis of infant universal routine pneu,Malaysia,Upper-middle,1,PCV13,PCV10,PCV13 vs PCV10,Four,1,Societal,US dollar,United States,2014,55,55,55,55,1,0,1,1,1,QALY gained,-5027,-5027,1,11319,Cost-saving,Cost-saving,-0.44,0.75,Cost-saving,0.45,Cost-saving,0.564443129,Cost-saving,0.317316947,Cost-saving,0.668688739,Cost-saving,0.277184384,Cost-saving,One GDPpc,Cost-saving,,,,,,,0,0,Industry
10,7,1007,Wu,2016,Cost-effectiveness analysis of infant universal routine pneu,Malaysia,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Four,0,Healthcare/payer,US dollar,United States,2014,55,55,,,0,0,1,1,1,QALY gained,15752,15752,0,11319,Not cost-effective,Cost-effective,1.39,0.75,Not cost-effective,0.45,Not cost-effective,0.564443129,Not cost-effective,0.317316947,Not cost-effective,0.668688739,Not cost-effective,0.277184384,Not cost-effective,One GDPpc,Not cost-effective,,,,,,,0,0,Industry
10,8,1008,Wu,2016,Cost-effectiveness analysis of infant universal routine pneu,Malaysia,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Four,0,Societal,US dollar,United States,2014,55,55,,,0,0,1,1,1,QALY gained,14981,14981,0,11319,Not cost-effective,Cost-effective,1.32,0.75,Not cost-effective,0.45,Not cost-effective,0.564443129,Not cost-effective,0.317316947,Not cost-effective,0.668688739,Not cost-effective,0.277184384,Not cost-effective,One GDPpc,Not cost-effective,,,,,,,0,0,Industry
11,1,1101,Krishnamoorthy,2019,Impact and cost effectiveness of pneumococcal conjugate vacc,India,Lower-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2017,3.3,3.3,,,0,0,1,1,1,DALY averted,467,467,0,1981,Cost-effective,Cost-effective,0.24,0.23,Not cost-effective,0.17,Not cost-effective,0.531177186,Cost-effective,0.079331658,Not cost-effective,0.294180445,Cost-effective,0.118529014,Not cost-effective,One GDPpc,Cost-effective,1,1,0,1,0,1,4,1,None
12,1,1201,Dilokthornsakul,2019,An updated cost-effectiveness analysis of pneumococcal conju,Thailand,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Four,0,Societal,Thai baht,Thailand,2018,1440,44.6,,,1,0,1,1,1,QALY gained,-46918,-1452,1,7297,Cost-saving,Cost-saving,-0.2,1.12,Cost-saving,0.7,Cost-saving,0.639240099,Cost-saving,0.191464001,Cost-saving,0.654853993,Cost-saving,0.271459303,Cost-saving,THB 160000,Cost-saving,,,,,,,0,1,Industry
12,2,1202,Dilokthornsakul,2019,An updated cost-effectiveness analysis of pneumococcal conju,Thailand,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Three,0,Societal,Thai baht,Thailand,2018,1440,44.6,,,1,0,1,1,1,QALY gained,-70854,-2193,1,7297,Cost-saving,Cost-saving,-0.3,1.12,Cost-saving,0.7,Cost-saving,0.639240099,Cost-saving,0.191464001,Cost-saving,0.654853993,Cost-saving,0.271459303,Cost-saving,THB 160000,Cost-saving,,,,,,,0,1,Industry
12,3,1203,Dilokthornsakul,2019,An updated cost-effectiveness analysis of pneumococcal conju,Thailand,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Four,0,Societal,Thai baht,Thailand,2018,1146,35.5,,,1,0,1,1,1,QALY gained,-84770,-2624,1,7297,Cost-saving,Cost-saving,-0.36,1.12,Cost-saving,0.7,Cost-saving,0.639240099,Cost-saving,0.191464001,Cost-saving,0.654853993,Cost-saving,0.271459303,Cost-saving,THB 160000,Cost-saving,,,,,,,0,1,Industry
12,4,1204,Dilokthornsakul,2019,An updated cost-effectiveness analysis of pneumococcal conju,Thailand,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,0,Societal,Thai baht,Thailand,2018,1146,35.5,,,1,0,1,1,1,QALY gained,-99394,-3076,1,7297,Cost-saving,Cost-saving,-0.42,1.12,Cost-saving,0.7,Cost-saving,0.639240099,Cost-saving,0.191464001,Cost-saving,0.654853993,Cost-saving,0.271459303,Cost-saving,THB 160000,Cost-saving,,,,,,,0,1,Industry
12,5,1205,Dilokthornsakul,2019,An updated cost-effectiveness analysis of pneumococcal conju,Thailand,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Four,0,Societal,Thai baht,Thailand,2018,1440,44.6,,,0,0,1,1,1,QALY gained,215948,6684,0,7297,Cost-effective,Cost-effective,0.92,1.12,Cost-effective,0.7,Not cost-effective,0.639240099,Not cost-effective,0.191464001,Not cost-effective,0.654853993,Not cost-effective,0.271459303,Not cost-effective,THB 160000,Not cost-effective,,,,,,,0,1,Industry
12,6,1206,Dilokthornsakul,2019,An updated cost-effectiveness analysis of pneumococcal conju,Thailand,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Three,1,Societal,Thai baht,Thailand,2018,1440,44.6,,,0,0,1,1,1,QALY gained,170437,5275,0,7297,Cost-effective,Cost-effective,0.72,1.12,Cost-effective,0.7,Not cost-effective,0.639240099,Not cost-effective,0.191464001,Not cost-effective,0.654853993,Not cost-effective,0.271459303,Not cost-effective,THB 160000,Not cost-effective,,,,,,,0,1,Industry
12,7,1207,Dilokthornsakul,2019,An updated cost-effectiveness analysis of pneumococcal conju,Thailand,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Four,0,Societal,Thai baht,Thailand,2018,1146,35.5,,,0,0,1,1,1,QALY gained,97269,3010,0,7297,Cost-effective,Cost-effective,0.41,1.12,Cost-effective,0.7,Cost-effective,0.639240099,Cost-effective,0.191464001,Not cost-effective,0.654853993,Cost-effective,0.271459303,Not cost-effective,THB 160000,Cost-effective,0,0,0,1,0,1,2,1,Industry
12,8,1208,Dilokthornsakul,2019,An updated cost-effectiveness analysis of pneumococcal conju,Thailand,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,1,Societal,Thai baht,Thailand,2018,1146,35.5,,,0,0,1,1,1,QALY gained,73674,2280,0,7297,Cost-effective,Cost-effective,0.31,1.12,Cost-effective,0.7,Cost-effective,0.639240099,Cost-effective,0.191464001,Not cost-effective,0.654853993,Cost-effective,0.271459303,Not cost-effective,THB 160000,Cost-effective,0,0,0,1,0,1,2,1,Industry
13,1,1301,Kulpeng,2013,Cost-utility analysis of 10-and 13-valent pneumococcal conju,Thailand,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Three,0,Societal,Thai baht,Thailand,2010,1440,45.4,,,1,1,1,1,1,QALY gained,519399,16392,0,5076,Not cost-effective,Not cost-effective,3.23,1.12,Not cost-effective,0.7,Not cost-effective,0.639240099,Not cost-effective,0.191464001,Not cost-effective,0.654853993,Not cost-effective,0.271459303,Not cost-effective,THB 100000,Not cost-effective,,,,,,,0,0,Non-profit
13,2,1302,Kulpeng,2013,Cost-utility analysis of 10-and 13-valent pneumococcal conju,Thailand,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Four,0,Societal,Thai baht,Thailand,2010,1440,45.4,,,1,1,1,1,1,QALY gained,650087,20517,0,5076,Not cost-effective,Not cost-effective,4.04,1.12,Not cost-effective,0.7,Not cost-effective,0.639240099,Not cost-effective,0.191464001,Not cost-effective,0.654853993,Not cost-effective,0.271459303,Not cost-effective,THB 100000,Not cost-effective,,,,,,,0,0,Non-profit
13,3,1303,Kulpeng,2013,Cost-utility analysis of 10-and 13-valent pneumococcal conju,Thailand,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Three,1,Societal,Thai baht,Thailand,2010,1440,45.4,,,0,0,1,1,1,QALY gained,1368072,43176,0,5076,Not cost-effective,Not cost-effective,8.51,1.12,Not cost-effective,0.7,Not cost-effective,0.639240099,Not cost-effective,0.191464001,Not cost-effective,0.654853993,Not cost-effective,0.271459303,Not cost-effective,THB 100000,Not cost-effective,,,,,,,0,0,Non-profit
13,4,1304,Kulpeng,2013,Cost-utility analysis of 10-and 13-valent pneumococcal conju,Thailand,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Four,0,Societal,Thai baht,Thailand,2010,1440,45.4,,,0,0,1,1,1,QALY gained,1677379,52938,0,5076,Not cost-effective,Not cost-effective,10.43,1.12,Not cost-effective,0.7,Not cost-effective,0.639240099,Not cost-effective,0.191464001,Not cost-effective,0.654853993,Not cost-effective,0.271459303,Not cost-effective,THB 100000,Not cost-effective,,,,,,,0,0,Non-profit
13,5,1305,Kulpeng,2013,Cost-utility analysis of 10-and 13-valent pneumococcal conju,Thailand,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,0,Societal,Thai baht,Thailand,2010,1930,60.9,,,1,1,1,1,1,QALY gained,527378,16644,0,5076,Not cost-effective,Not cost-effective,3.28,1.12,Not cost-effective,0.7,Not cost-effective,0.639240099,Not cost-effective,0.191464001,Not cost-effective,0.654853993,Not cost-effective,0.271459303,Not cost-effective,THB 100000,Not cost-effective,,,,,,,0,0,Non-profit
13,6,1306,Kulpeng,2013,Cost-utility analysis of 10-and 13-valent pneumococcal conju,Thailand,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Four,0,Societal,Thai baht,Thailand,2010,1930,60.9,,,1,1,1,1,1,QALY gained,660662,20850,0,5076,Not cost-effective,Not cost-effective,4.11,1.12,Not cost-effective,0.7,Not cost-effective,0.639240099,Not cost-effective,0.191464001,Not cost-effective,0.654853993,Not cost-effective,0.271459303,Not cost-effective,THB 100000,Not cost-effective,,,,,,,0,0,Non-profit
13,7,1307,Kulpeng,2013,Cost-utility analysis of 10-and 13-valent pneumococcal conju,Thailand,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,1,Societal,Thai baht,Thailand,2010,1930,60.9,,,0,0,1,1,1,QALY gained,1490305,47034,0,5076,Not cost-effective,Not cost-effective,9.27,1.12,Not cost-effective,0.7,Not cost-effective,0.639240099,Not cost-effective,0.191464001,Not cost-effective,0.654853993,Not cost-effective,0.271459303,Not cost-effective,THB 100000,Not cost-effective,,,,,,,0,0,Non-profit
13,8,1308,Kulpeng,2013,Cost-utility analysis of 10-and 13-valent pneumococcal conju,Thailand,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Four,0,Societal,Thai baht,Thailand,2010,1930,60.9,,,0,0,1,1,1,QALY gained,1830716,57777,0,5076,Not cost-effective,Not cost-effective,11.38,1.12,Not cost-effective,0.7,Not cost-effective,0.639240099,Not cost-effective,0.191464001,Not cost-effective,0.654853993,Not cost-effective,0.271459303,Not cost-effective,THB 100000,Not cost-effective,,,,,,,0,0,Non-profit
14,1,1401,Haasis,2015,Do pneumococcal conjugate vaccines represent good value for ,Philippines,Lower-middle,1,PCV10,NoVax,PCV10 vs NoVax,Three,1,Healthcare/payer,Philippine peso,Philippines,2013,624,14.7,,,1,0,1,1,1,QALY gained,68182,1606,0,2871,Cost-effective,Cost-effective,0.56,0.34,Not cost-effective,0.23,Not cost-effective,0.494875427,Not cost-effective,0.089154194,Not cost-effective,0.401969294,Not cost-effective,0.161820615,Not cost-effective,"PHP 120,000",Cost-effective,1,1,1,1,1,1,6,1,Non-profit
14,2,1402,Haasis,2015,Do pneumococcal conjugate vaccines represent good value for ,Philippines,Lower-middle,1,PCV10,NoVax,PCV10 vs NoVax,Three,0,Healthcare/payer,Philippine peso,Philippines,2013,624,14.7,,,0,0,1,1,1,QALY gained,112640,2654,0,2871,Cost-effective,Cost-effective,0.92,0.34,Not cost-effective,0.23,Not cost-effective,0.494875427,Not cost-effective,0.089154194,Not cost-effective,0.401969294,Not cost-effective,0.161820615,Not cost-effective,"PHP 120,000",Cost-effective,1,1,1,1,1,1,6,1,Non-profit
14,3,1403,Haasis,2015,Do pneumococcal conjugate vaccines represent good value for ,Philippines,Lower-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,1,Healthcare/payer,Philippine peso,Philippines,2013,700,16.5,,,1,0,1,1,1,QALY gained,54510,1284,0,2871,Cost-effective,Cost-effective,0.45,0.34,Not cost-effective,0.23,Not cost-effective,0.494875427,Cost-effective,0.089154194,Not cost-effective,0.401969294,Not cost-effective,0.161820615,Not cost-effective,"PHP 120,000",Cost-effective,1,1,0,1,1,1,5,1,Non-profit
14,4,1404,Haasis,2015,Do pneumococcal conjugate vaccines represent good value for ,Philippines,Lower-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,0,Healthcare/payer,Philippine peso,Philippines,2013,700,16.5,,,0,0,1,1,1,QALY gained,84654,1994,0,2871,Cost-effective,Cost-effective,0.69,0.34,Not cost-effective,0.23,Not cost-effective,0.494875427,Not cost-effective,0.089154194,Not cost-effective,0.401969294,Not cost-effective,0.161820615,Not cost-effective,"PHP 120,000",Cost-effective,1,1,1,1,1,1,6,1,Non-profit
14,5,1405,Haasis,2015,Do pneumococcal conjugate vaccines represent good value for ,Philippines,Lower-middle,1,PCV13,PCV10,PCV13 vs PCV10,Three,1,Healthcare/payer,Philippine peso,Philippines,2013,700,16.5,624,14.7,1,0,1,1,1,QALY gained,15795,372,0,2871,Cost-effective,Cost-effective,0.13,0.34,Cost-effective,0.23,Cost-effective,0.494875427,Cost-effective,0.089154194,Not cost-effective,0.401969294,Cost-effective,0.161820615,Cost-effective,"PHP 120,000",Cost-effective,0,0,0,1,0,0,1,1,Non-profit
14,6,1406,Haasis,2015,Do pneumococcal conjugate vaccines represent good value for ,Philippines,Lower-middle,1,PCV13,PCV10,PCV13 vs PCV10,Three,0,Healthcare/payer,Philippine peso,Philippines,2013,700,16.5,624,14.7,0,0,1,1,1,QALY gained,23836,562,0,2871,Cost-effective,Cost-effective,0.2,0.34,Cost-effective,0.23,Cost-effective,0.494875427,Cost-effective,0.089154194,Not cost-effective,0.401969294,Cost-effective,0.161820615,Not cost-effective,"PHP 120,000",Cost-effective,0,0,0,1,0,1,2,1,Non-profit
15,1,1501,Zhang,2014,Cost-effectiveness analysis of pneumococcal vaccination with,Philippines,Lower-middle,1,PCV10,NoVax,PCV10 vs NoVax,Three,1,Healthcare/payer,Philippine peso,Philippines,2012,800,18.9,,,0,1,1,1,1,QALY gained,50913,1206,0,2694,Cost-effective,Cost-effective,0.45,0.34,Not cost-effective,0.23,Not cost-effective,0.494875427,Cost-effective,0.089154194,Not cost-effective,0.401969294,Not cost-effective,0.161820615,Not cost-effective,One GDPpc,Cost-effective,1,1,0,1,1,1,5,0,Industry
15,2,1502,Zhang,2014,Cost-effectiveness analysis of pneumococcal vaccination with,Philippines,Lower-middle,1,PCV13,PCV10,PCV13 vs PCV10,Three,1,Healthcare/payer,Philippine peso,Philippines,2012,800,18.9,800,18.9,0,1,1,1,1,QALY gained,310275,7347,0,2694,Not cost-effective,Cost-effective,2.73,0.34,Not cost-effective,0.23,Not cost-effective,0.494875427,Not cost-effective,0.089154194,Not cost-effective,0.401969294,Not cost-effective,0.161820615,Not cost-effective,One GDPpc,Not cost-effective,,,,,,,0,0,Industry
16,1,1601,Sundaram,2017,Cost-effectiveness of 13-valent pneumococcal conjugate vacci,Mongolia,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,1,Societal,US dollar,United States,2014,3.3,3.3,,,1,1,1,1,1,DALY averted,-27,-27,1,4159,Cost-saving,Cost-saving,-0.01,0.49,Cost-saving,0.35,Cost-saving,0.477544032,Cost-saving,0.124367582,Cost-saving,0.362101209,Cost-saving,0.145748574,Cost-saving,One GDPpc,Cost-saving,,,,,,,0,1,Non-profit
16,2,1602,Sundaram,2017,Cost-effectiveness of 13-valent pneumococcal conjugate vacci,Mongolia,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2014,3.3,3.3,,,1,1,1,1,1,DALY averted,52,52,0,4159,Cost-effective,Cost-effective,0.01,0.49,Cost-effective,0.35,Cost-effective,0.477544032,Cost-effective,0.124367582,Cost-effective,0.362101209,Cost-effective,0.145748574,Cost-effective,One GDPpc,Cost-effective,0,0,0,0,0,0,0,1,Non-profit
16,3,1603,Sundaram,2017,Cost-effectiveness of 13-valent pneumococcal conjugate vacci,Mongolia,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,0,Societal,US dollar,United States,2014,3.3,3.3,,,0,0,1,1,1,DALY averted,19,19,0,4159,Cost-effective,Cost-effective,0,0.49,Cost-effective,0.35,Cost-effective,0.477544032,Cost-effective,0.124367582,Cost-effective,0.362101209,Cost-effective,0.145748574,Cost-effective,One GDPpc,Cost-effective,0,0,0,0,0,0,0,1,Non-profit
16,4,1604,Sundaram,2017,Cost-effectiveness of 13-valent pneumococcal conjugate vacci,Mongolia,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,0,Healthcare/payer,US dollar,United States,2014,3.3,3.3,,,0,0,1,1,1,DALY averted,79,79,0,4159,Cost-effective,Cost-effective,0.02,0.49,Cost-effective,0.35,Cost-effective,0.477544032,Cost-effective,0.124367582,Cost-effective,0.362101209,Cost-effective,0.145748574,Cost-effective,One GDPpc,Cost-effective,0,0,0,0,0,0,0,1,Non-profit
17,1,1701,Dorji,2018,Towards the introduction of pneumococcal conjugate vaccines ,Bhutan,Lower-middle,1,PCV10,NoVax,PCV10 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2017,3.1,3.1,,,1,0,1,1,1,QALY gained,36,36,0,3287,Cost-effective,Cost-effective,0.01,,NA,,NA,0.508750518,Cost-effective,0.107978051,Cost-effective,0.342174771,Cost-effective,0.137832933,Cost-effective,One GDPpc,Cost-effective,0,0,0,0,0,0,0,1,Non-profit
17,2,1702,Dorji,2018,Towards the introduction of pneumococcal conjugate vaccines ,Bhutan,Lower-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2017,3.6,3.6,,,1,0,1,1,1,QALY gained,40,40,0,3287,Cost-effective,Cost-effective,0.01,,NA,,NA,0.508750518,Cost-effective,0.107978051,Cost-effective,0.342174771,Cost-effective,0.137832933,Cost-effective,One GDPpc,Cost-effective,0,0,0,0,0,0,0,1,Non-profit
17,3,1703,Dorji,2018,Towards the introduction of pneumococcal conjugate vaccines ,Bhutan,Lower-middle,1,PCV13,PCV10,PCV13 vs PCV10,Three,1,Healthcare/payer,US dollar,United States,2017,3.6,3.6,3.05,3.1,1,0,1,1,1,QALY gained,92,92,0,3287,Cost-effective,Cost-effective,0.03,,NA,,NA,0.508750518,Cost-effective,0.107978051,Cost-effective,0.342174771,Cost-effective,0.137832933,Cost-effective,One GDPpc,Cost-effective,0,0,0,0,0,0,0,1,Non-profit
18,1,1801,Constenla,2008,Economic impact of pneumococcal conjugate vaccination in Bra,Brazil,Lower-middle,0,PCV7,NoVax,PCV7 vs NoVax,Three,1,Societal,US dollar,United States,2004,53,53,,,0,0,1,1,1,DALY averted,664,664,0,3637,Cost-effective,Cost-effective,0.18,1.09,Cost-effective,0.71,Cost-effective,0.613314051,Cost-effective,0.194546729,Cost-effective,1.673943393,Cost-effective,0.693786261,Cost-effective,Three GDPpc,Cost-effective,0,0,0,0,0,0,0,0,Non-profit
18,2,1802,Constenla,2008,Economic impact of pneumococcal conjugate vaccination in Bra,Uruguay,Upper-middle,0,PCV7,NoVax,PCV7 vs NoVax,Three,1,Societal,US dollar,United States,2004,53,53,,,0,0,1,1,1,DALY averted,1546,1546,0,4121,Cost-effective,Cost-effective,0.38,,NA,,NA,0.597807575,Cost-effective,0.267944107,Not cost-effective,0.989709698,Cost-effective,0.672602324,Cost-effective,Three GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Non-profit
19,1,1901,Vespa,2009,Estimating the cost-effectiveness of pneumococcal conjugate ,Brazil,Upper-middle,0,PCV7,NoVax,PCV7 vs NoVax,Three,1,Healthcare/payer,Brazilian real,Brazil,2006,51.1,23.5,,,0,0,1,1,1,DALY averted,4516,2076,0,5886,Cost-effective,Cost-effective,0.35,1.09,Cost-effective,0.71,Cost-effective,0.613314051,Cost-effective,0.194546729,Not cost-effective,1.673943393,Cost-effective,0.693786261,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Industry
19,2,1902,Vespa,2009,Estimating the cost-effectiveness of pneumococcal conjugate ,Brazil,Upper-middle,0,PCV7,NoVax,PCV7 vs NoVax,Three,1,Societal,Brazilian real,Brazil,2006,51.1,23.5,,,0,0,1,1,1,DALY averted,3946,1814,0,5886,Cost-effective,Cost-effective,0.31,1.09,Cost-effective,0.71,Cost-effective,0.613314051,Cost-effective,0.194546729,Not cost-effective,1.673943393,Cost-effective,0.693786261,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Industry
19,3,1903,Vespa,2009,Estimating the cost-effectiveness of pneumococcal conjugate ,Brazil,Upper-middle,0,PCV7,NoVax,PCV7 vs NoVax,Three,0,Societal,Brazilian real,Brazil,2006,51.1,23.5,,,1,0,1,1,1,DALY averted,1302,599,0,5886,Cost-effective,Cost-effective,0.1,1.09,Cost-effective,0.71,Cost-effective,0.613314051,Cost-effective,0.194546729,Cost-effective,1.673943393,Cost-effective,0.693786261,Cost-effective,One GDPpc,Cost-effective,0,0,0,0,0,0,0,0,Industry
19,4,1904,Vespa,2009,Estimating the cost-effectiveness of pneumococcal conjugate ,Brazil,Upper-middle,0,PCV7,NoVax,PCV7 vs NoVax,Three,0,Healthcare/payer,Brazilian real,Brazil,2006,51.1,23.5,,,1,0,1,1,1,DALY averted,1490,685,0,5886,Cost-effective,Cost-effective,0.12,1.09,Cost-effective,0.71,Cost-effective,0.613314051,Cost-effective,0.194546729,Cost-effective,1.673943393,Cost-effective,0.693786261,Cost-effective,One GDPpc,Cost-effective,0,0,0,0,0,0,0,0,Industry
19,5,1905,Vespa,2009,Estimating the cost-effectiveness of pneumococcal conjugate ,Brazil,Upper-middle,0,PCV7,NoVax,PCV7 vs NoVax,Four,1,Healthcare/payer,Brazilian real,Brazil,2006,51.1,23.5,,,0,0,1,1,1,DALY averted,5973,2746,0,5886,Cost-effective,Cost-effective,0.47,1.09,Cost-effective,0.71,Cost-effective,0.613314051,Cost-effective,0.194546729,Not cost-effective,1.673943393,Cost-effective,0.693786261,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Industry
19,6,1906,Vespa,2009,Estimating the cost-effectiveness of pneumococcal conjugate ,Brazil,Upper-middle,0,PCV7,NoVax,PCV7 vs NoVax,Four,1,Societal,Brazilian real,Brazil,2006,51.1,23.5,,,0,0,1,1,1,DALY averted,5403,2484,0,5886,Cost-effective,Cost-effective,0.42,1.09,Cost-effective,0.71,Cost-effective,0.613314051,Cost-effective,0.194546729,Not cost-effective,1.673943393,Cost-effective,0.693786261,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Industry
20,1,2001,Kim,2010,Economic evaluation of pneumococcal conjugate vaccination in,"Gambia, The",Low,0,PCV9,NoVax,Others,Three,1,Societal,US dollar,United States,2005,3.5,3.5,,,0,0,1,1,0,DALY averted,670,670,0,666,Not cost-effective,Cost-effective,1.01,0.69,Not cost-effective,0.52,Not cost-effective,0.359734802,Not cost-effective,0.017130229,Not cost-effective,0.255166171,Not cost-effective,0.05051513,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Non-profit
20,2,2002,Kim,2010,Economic evaluation of pneumococcal conjugate vaccination in,"Gambia, The",Low,0,PCV7,NoVax,PCV7 vs NoVax,Three,1,Societal,US dollar,United States,2005,3.5,3.5,,,0,0,1,1,0,DALY averted,910,910,0,666,Not cost-effective,Cost-effective,1.37,0.69,Not cost-effective,0.52,Not cost-effective,0.359734802,Not cost-effective,0.017130229,Not cost-effective,0.255166171,Not cost-effective,0.05051513,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Non-profit
20,3,2003,Kim,2010,Economic evaluation of pneumococcal conjugate vaccination in,"Gambia, The",Low,0,PCV10,NoVax,PCV10 vs NoVax,Three,1,Societal,US dollar,United States,2005,3.5,3.5,,,0,0,1,1,0,DALY averted,670,670,0,666,Not cost-effective,Cost-effective,1.01,0.69,Not cost-effective,0.52,Not cost-effective,0.359734802,Not cost-effective,0.017130229,Not cost-effective,0.255166171,Not cost-effective,0.05051513,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Non-profit
20,4,2004,Kim,2010,Economic evaluation of pneumococcal conjugate vaccination in,"Gambia, The",Low,0,PCV13,NoVax,PCV13 vs NoVax,Three,1,Societal,US dollar,United States,2005,3.5,3.5,,,0,0,1,1,0,DALY averted,570,570,0,666,Cost-effective,Cost-effective,0.86,0.69,Not cost-effective,0.52,Not cost-effective,0.359734802,Not cost-effective,0.017130229,Not cost-effective,0.255166171,Not cost-effective,0.05051513,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Non-profit
20,5,2005,Kim,2010,Economic evaluation of pneumococcal conjugate vaccination in,"Gambia, The",Low,0,PCV7,NoVax,PCV7 vs NoVax,Three,0,Societal,US dollar,United States,2005,3.5,3.5,,,1,1,1,1,0,DALY averted,830,830,0,666,Not cost-effective,Cost-effective,1.25,0.69,Not cost-effective,0.52,Not cost-effective,0.359734802,Not cost-effective,0.017130229,Not cost-effective,0.255166171,Not cost-effective,0.05051513,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Non-profit
20,6,2006,Kim,2010,Economic evaluation of pneumococcal conjugate vaccination in,"Gambia, The",Low,0,PCV10,NoVax,PCV10 vs NoVax,Three,0,Societal,US dollar,United States,2005,3.5,3.5,,,1,1,1,1,0,DALY averted,550,550,0,666,Cost-effective,Cost-effective,0.83,0.69,Not cost-effective,0.52,Not cost-effective,0.359734802,Not cost-effective,0.017130229,Not cost-effective,0.255166171,Not cost-effective,0.05051513,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Non-profit
20,7,2007,Kim,2010,Economic evaluation of pneumococcal conjugate vaccination in,"Gambia, The",Low,0,PCV13,NoVax,PCV13 vs NoVax,Three,0,Societal,US dollar,United States,2005,3.5,3.5,,,1,1,1,1,0,DALY averted,480,480,0,666,Cost-effective,Cost-effective,0.72,0.69,Not cost-effective,0.52,Not cost-effective,0.359734802,Not cost-effective,0.017130229,Not cost-effective,0.255166171,Not cost-effective,0.05051513,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Non-profit
21,1,2101,Urueña,2011,Cost-effectiveness analysis of the 10- and 13-valent pneumoc,Argentina,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2009,20.8,20.8,,,0,0,1,1,1,DALY averted,8973,8973,0,8225,Not cost-effective,Cost-effective,1.09,0.56,Not cost-effective,0.37,Not cost-effective,,NA,,NA,1.63265299,Cost-effective,0.676667495,Not cost-effective,Three GDPpc,Cost-effective,1,1,0,0,0,1,3,0,None
21,2,2102,Urueña,2011,Cost-effectiveness analysis of the 10- and 13-valent pneumoc,Argentina,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,0,Societal,US dollar,United States,2009,20.8,20.8,,,0,0,1,1,1,DALY averted,8546,8546,0,8225,Not cost-effective,Cost-effective,1.04,0.56,Not cost-effective,0.37,Not cost-effective,,NA,,NA,1.63265299,Cost-effective,0.676667495,Not cost-effective,Three GDPpc,Cost-effective,1,1,0,0,0,1,3,0,None
21,3,2103,Urueña,2011,Cost-effectiveness analysis of the 10- and 13-valent pneumoc,Argentina,Upper-middle,0,PCV13,NoVax,PCV13 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2009,20.8,20.8,,,0,0,1,1,1,DALY averted,10948,10948,0,8225,Not cost-effective,Cost-effective,1.33,0.56,Not cost-effective,0.37,Not cost-effective,,NA,,NA,1.63265299,Cost-effective,0.676667495,Not cost-effective,Three GDPpc,Cost-effective,1,1,0,0,0,1,3,0,None
21,4,2104,Urueña,2011,Cost-effectiveness analysis of the 10- and 13-valent pneumoc,Argentina,Upper-middle,0,PCV13,NoVax,PCV13 vs NoVax,Four,0,Societal,US dollar,United States,2009,20.8,20.8,,,0,0,1,1,1,DALY averted,10510,10510,0,8225,Not cost-effective,Cost-effective,1.28,0.56,Not cost-effective,0.37,Not cost-effective,,NA,,NA,1.63265299,Cost-effective,0.676667495,Not cost-effective,Three GDPpc,Cost-effective,1,1,0,0,0,1,3,0,None
21,5,2105,Urueña,2011,Cost-effectiveness analysis of the 10- and 13-valent pneumoc,Argentina,Upper-middle,0,PCV13,PCV10,PCV13 vs PCV10,Four,1,Healthcare/payer,US dollar,United States,2009,20.8,20.8,20.75,20.8,0,0,1,1,1,DALY averted,28147,28147,0,8225,Not cost-effective,Not cost-effective,3.42,0.56,Not cost-effective,0.37,Not cost-effective,,NA,,NA,1.63265299,Not cost-effective,0.676667495,Not cost-effective,Three GDPpc,Cost-effective,1,1,0,0,1,1,4,0,None
21,6,2106,Urueña,2011,Cost-effectiveness analysis of the 10- and 13-valent pneumoc,Argentina,Upper-middle,0,PCV13,PCV10,PCV13 vs PCV10,Four,0,Societal,US dollar,United States,2009,20.8,20.8,20.75,20.8,0,0,1,1,1,DALY averted,27614,27614,0,8225,Not cost-effective,Not cost-effective,3.36,0.56,Not cost-effective,0.37,Not cost-effective,,NA,,NA,1.63265299,Not cost-effective,0.676667495,Not cost-effective,Three GDPpc,Cost-effective,1,1,0,0,1,1,4,0,None
22,1,2201,Touray,2011,The cost effectiveness of pneumococcal conjugate vaccine in ,"Gambia, The",Low,0,PCV9,NoVax,Others,Three,1,Societal,US dollar,United States,2005,5,5,,,0,0,1,1,0,DALY averted,26,26,0,666,Cost-effective,Cost-effective,0.04,0.69,Cost-effective,0.52,Cost-effective,0.359734802,Cost-effective,0.017130229,Not cost-effective,0.255166171,Cost-effective,0.05051513,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,1,None
23,1,2301,Ayieko,2013,Assessment of health benefits and cost-effectiveness of 10-v,Kenya,Low,0,PCV10,NoVax,PCV10 vs NoVax,One/two,1,Societal,US dollar,United States,2010,3.5,3.5,,,0,0,1,1,0,DALY averted,59,59,0,1080,Cost-effective,Cost-effective,0.05,0.47,Cost-effective,0.36,Cost-effective,0.383076483,Cost-effective,0.023619359,Not cost-effective,0.405720265,Cost-effective,0.163124643,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Non-profit
23,2,2302,Ayieko,2013,Assessment of health benefits and cost-effectiveness of 10-v,Kenya,Low,0,PCV13,NoVax,PCV13 vs NoVax,One/two,1,Societal,US dollar,United States,2010,3.5,3.5,,,0,0,1,1,0,DALY averted,47,47,0,1080,Cost-effective,Cost-effective,0.04,0.47,Cost-effective,0.36,Cost-effective,0.383076483,Cost-effective,0.023619359,Not cost-effective,0.405720265,Cost-effective,0.163124643,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Non-profit
23,3,2303,Ayieko,2013,Assessment of health benefits and cost-effectiveness of 10-v,Kenya,Low,0,PCV10,NoVax,PCV10 vs NoVax,One/two,0,Societal,US dollar,United States,2010,3.5,3.5,,,1,1,1,1,0,DALY averted,32,32,0,1080,Cost-effective,Cost-effective,0.03,0.47,Cost-effective,0.36,Cost-effective,0.383076483,Cost-effective,0.023619359,Not cost-effective,0.405720265,Cost-effective,0.163124643,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Non-profit
23,4,2304,Ayieko,2013,Assessment of health benefits and cost-effectiveness of 10-v,Kenya,Low,0,PCV13,NoVax,PCV13 vs NoVax,One/two,0,Societal,US dollar,United States,2010,3.5,3.5,,,1,1,1,1,0,DALY averted,25,25,0,1080,Cost-effective,Cost-effective,0.02,0.47,Cost-effective,0.36,Cost-effective,0.383076483,Cost-effective,0.023619359,Cost-effective,0.405720265,Cost-effective,0.163124643,Cost-effective,One GDPpc,Cost-effective,0,0,0,0,0,0,0,0,Non-profit
24,1,2401,Gargano,2015,Pneumonia Prevention during a Humanitarian Emergency: Cost-e,Somalia,Low,0,PCV10,NoVax,PCV10 vs NoVax,One/two,1,Healthcare/payer,US dollar,United States,2011,7,7,,,0,0,1,0,0,DALY averted,115,115,0,298,Cost-effective,Cost-effective,0.39,,NA,,NA,,NA,,NA,,NA,,NA,Three GDPpc,Cost-effective,0,0,0,0,0,0,0,0,None
24,2,2402,Gargano,2015,Pneumonia Prevention during a Humanitarian Emergency: Cost-e,Somalia,Low,0,PCV10,NoVax,PCV10 vs NoVax,One/two,1,Healthcare/payer,US dollar,United States,2011,7,7,,,0,0,1,0,0,DALY averted,162,162,0,298,Cost-effective,Cost-effective,0.54,,NA,,NA,,NA,,NA,,NA,,NA,Three GDPpc,Cost-effective,0,0,0,0,0,0,0,0,None
25,1,2501,Sibak,2015,Cost-effectiveness analysis of the introduction of the pneum,"Egypt, Arab Rep.",Lower-middle,0,PCV13,NoVax,PCV13 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2013,14.2,14.2,,,1,1,1,1,1,DALY averted,3916,3916,0,3263,Not cost-effective,Cost-effective,1.2,0.41,Not cost-effective,0.27,Not cost-effective,0.61085172,Not cost-effective,0.159992272,Not cost-effective,0.49220092,Not cost-effective,0.198072779,Not cost-effective,One/Three GPDpc,Cost-effective,1,1,1,1,1,1,6,0,Non-profit
26,1,2601,Mezones,2015,Cost-effectiveness analysis of 10- and 13-valent pneumococca,Peru,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2012,14.2,14.2,,,0,0,1,1,1,DALY averted,1605,1605,0,6529,Cost-effective,Cost-effective,0.25,1.08,Cost-effective,0.64,Cost-effective,0.648684361,Cost-effective,0.164872092,Not cost-effective,0.884510957,Cost-effective,0.36655409,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,1,Non-profit
26,2,2602,Mezones,2015,Cost-effectiveness analysis of 10- and 13-valent pneumococca,Peru,Upper-middle,0,PCV13,NoVax,PCV13 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2012,16.3,16.3,,,0,0,1,1,1,DALY averted,1304,1304,0,6529,Cost-effective,Cost-effective,0.2,1.08,Cost-effective,0.64,Cost-effective,0.648684361,Cost-effective,0.164872092,Not cost-effective,0.884510957,Cost-effective,0.36655409,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,1,Non-profit
26,3,2603,Mezones,2015,Cost-effectiveness analysis of 10- and 13-valent pneumococca,Peru,Upper-middle,0,PCV13,PCV10,PCV13 vs PCV10,Four,1,Healthcare/payer,US dollar,United States,2012,16.3,16.3,14.24,14.2,0,0,1,1,1,DALY averted,519,519,0,6529,Cost-effective,Cost-effective,0.08,1.08,Cost-effective,0.64,Cost-effective,0.648684361,Cost-effective,0.164872092,Cost-effective,0.884510957,Cost-effective,0.36655409,Cost-effective,One GDPpc,Cost-effective,0,0,0,0,0,0,0,1,Non-profit
27,1,2701,Gargano,2017,Pneumonia prevention: Cost-effectiveness analyses of two vac,South Sudan,Lower-middle,0,PCV9,NoVax,Others,One/two,1,Healthcare/payer,US dollar,United States,2013,8,8,,,0,0,1,0,0,DALY averted,148,148,0,1779,Cost-effective,Cost-effective,0.08,,NA,,NA,0.346732383,Cost-effective,0.022478599,Not cost-effective,,NA,,NA,One GDPpc,Cost-effective,0,0,0,1,0,0,1,0,None
27,2,2702,Gargano,2017,Pneumonia prevention: Cost-effectiveness analyses of two vac,South Sudan,Lower-middle,0,PCV9,NoVax,Others,One/two,1,Healthcare/payer,US dollar,United States,2013,8,8,,,0,0,1,0,0,DALY averted,210,210,0,1779,Cost-effective,Cost-effective,0.12,,NA,,NA,0.346732383,Cost-effective,0.022478599,Not cost-effective,,NA,,NA,One GDPpc,Cost-effective,0,0,0,1,0,0,1,0,None
28,1,2801,Kupek,2018,Postintroduction Study of Cost Effectiveness of Pneumococcal,Brazil,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2014,,,,,0,0,1,1,0,DALY averted,27748,27748,0,12113,Not cost-effective,Cost-effective,2.29,1.09,Not cost-effective,0.71,Not cost-effective,0.613314051,Not cost-effective,0.194546729,Not cost-effective,1.673943393,Not cost-effective,0.693786261,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,None
29,1,2901,Lara,2018,Cost-Effectiveness Analysis of Pneumococcal and Influenza Va,Colombia,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Three,1,Healthcare/payer,Intl Dollars,International,2008,20,10.8,,,0,0,1,1,1,DALY averted,1417,762,0,5473,Cost-effective,Cost-effective,0.14,1.89,Cost-effective,1.17,Cost-effective,0.671424489,Cost-effective,0.166700172,Cost-effective,1.323739634,Cost-effective,0.548639884,Cost-effective,One GDPpc,Cost-effective,0,0,0,0,0,0,0,0,None
29,2,2902,Lara,2018,Cost-Effectiveness Analysis of Pneumococcal and Influenza Va,Colombia,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Three,1,Societal,Intl Dollars,International,2008,20,10.8,,,0,0,1,1,1,DALY averted,1301,699,0,5473,Cost-effective,Cost-effective,0.13,1.89,Cost-effective,1.17,Cost-effective,0.671424489,Cost-effective,0.166700172,Cost-effective,1.323739634,Cost-effective,0.548639884,Cost-effective,One GDPpc,Cost-effective,0,0,0,0,0,0,0,0,None
30,1,3001,Kebede,2019,Cost-effectiveness of childhood pneumococcal vaccination pro,Ethiopia,Low,0,PCV10,NoVax,PCV10 vs NoVax,Three,1,Societal,US dollar,United States,2013,6.5,6.5,,,0,0,1,1,1,DALY averted,268,268,0,500,Cost-effective,Cost-effective,0.54,0.36,Not cost-effective,0.27,Not cost-effective,0.510478287,Not cost-effective,0.020018756,Not cost-effective,0.22669884,Not cost-effective,0.045573478,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Non-profit
30,2,3002,Kebede,2019,Cost-effectiveness of childhood pneumococcal vaccination pro,Ethiopia,Low,0,PCV10,NoVax,PCV10 vs NoVax,Three,1,Societal,US dollar,United States,2013,6.5,6.5,,,0,0,1,1,1,DALY averted,293,281,0,500,Cost-effective,Cost-effective,0.56,0.36,Not cost-effective,0.27,Not cost-effective,0.510478287,Not cost-effective,0.020018756,Not cost-effective,0.22669884,Not cost-effective,0.045573478,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Non-profit
31,1,3101,Ojal,2019,Sustaining pneumococcal vaccination after transitioning from,Kenya,Lower-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,1,Societal,US dollar,United States,2016,3.1,3.1,,,0,0,1,1,0,DALY averted,153,153,0,1525,Cost-effective,Cost-effective,0.1,0.47,Cost-effective,0.36,Cost-effective,0.383076483,Cost-effective,0.023619359,Not cost-effective,0.405720265,Cost-effective,0.163124643,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,1,Mixed
32,1,3201,Ezoji,2019,Cost-effectiveness of introducing the pneumococcal conjugate,"Iran, Islamic Rep.",Upper-middle,0,PCV13,NoVax,PCV13 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2014,20,20,,,0,0,1,1,1,DALY averted,1890,1890,0,5586,Cost-effective,Cost-effective,0.34,,NA,,NA,0.526890972,Cost-effective,0.175131846,Not cost-effective,2.656822561,Cost-effective,1.100935899,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Non-profit
32,2,3202,Ezoji,2019,Cost-effectiveness of introducing the pneumococcal conjugate,"Iran, Islamic Rep.",Upper-middle,0,PCV13,NoVax,PCV13 vs NoVax,Three,1,Societal,US dollar,United States,2014,20,20,,,0,0,1,1,1,DALY averted,1538,1538,0,5586,Cost-effective,Cost-effective,0.28,,NA,,NA,0.526890972,Cost-effective,0.175131846,Not cost-effective,2.656822561,Cost-effective,1.100935899,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Non-profit
33,1,3301,Fariñas,2020,Cost-effectiveness of introducing a domestic pneumococcal co,Cuba,Upper-middle,0,PCV7,NoVax,PCV7 vs NoVax,Three,1,Healthcare/payer,Cuban peso,Cuba,2016,7,0.3,,,0,0,1,1,1,DALY averted,374,16,0,8061,Cost-effective,Cost-effective,0,,NA,,NA,,NA,,NA,2.051638057,Cost-effective,0.850329078,Cost-effective,One GDPpc,Cost-effective,0,0,0,0,0,0,0,0,Mixed
34,1,3401,Bakir,2012,Cost-effectiveness of new pneumococcal conjugate vaccines in,Turkey,Upper-middle,0,PCV13,PCV7,Others,Four,1,Healthcare/payer,US dollar,United States,2011,55,55,55,55,0,0,1,1,1,QALY gained,-1567,-2223,1,11421,Cost-saving,Cost-saving,-0.19,1.43,Cost-saving,0.82,Cost-saving,0.543885753,Cost-saving,0.233852641,Cost-saving,0.760180724,Cost-saving,0.315079233,Cost-saving,NA,Cost-saving,,,,,,,0,0,Industry
34,2,3402,Bakir,2012,Cost-effectiveness of new pneumococcal conjugate vaccines in,Turkey,Upper-middle,0,PCV13,PCV10,PCV13 vs PCV10,Four,1,Healthcare/payer,US dollar,United States,2011,55,55,55,55,0,0,1,1,1,QALY gained,999999,999999,0,11421,Not cost-effective,Not cost-effective,87.56,1.43,Not cost-effective,0.82,Not cost-effective,0.543885753,Not cost-effective,0.233852641,Not cost-effective,0.760180724,Not cost-effective,0.315079233,Not cost-effective,NA,Not cost-effective,,,,,,,0,0,Industry
34,3,3403,Bakir,2012,Cost-effectiveness of new pneumococcal conjugate vaccines in,Turkey,Upper-middle,0,PCV10,PCV7,Others,Four,1,Healthcare/payer,US dollar,United States,2000,55,55,55,55,0,0,1,1,1,QALY gained,-3713,-3156,1,4337,Cost-saving,Cost-saving,-0.73,1.43,Cost-saving,0.82,Cost-saving,0.543885753,Cost-saving,0.233852641,Cost-saving,0.760180724,Cost-saving,0.315079233,Cost-saving,NA,Cost-saving,,,,,,,0,0,Industry
35,1,3501,Castañeda-Orjuela,2012,"Cost-effectiveness of pneumococcal conjugate vaccines of 7, ",Colombia,Upper-middle,0,PCV7,NoVax,PCV7 vs NoVax,Three,1,Societal,US dollar,United States,2009,14,14,,,0,0,1,1,1,LY gained,999999,999999,0,5193,Not cost-effective,Not cost-effective,192.56,1.89,Not cost-effective,1.17,Not cost-effective,0.671424489,Not cost-effective,0.166700172,Not cost-effective,1.323739634,Not cost-effective,0.548639884,Not cost-effective,One GDPpc,Not cost-effective,,,,,,,0,0,Government
35,2,3502,Castañeda-Orjuela,2012,"Cost-effectiveness of pneumococcal conjugate vaccines of 7, ",Colombia,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Three,1,Societal,US dollar,United States,2009,14.9,14.9,,,0,0,1,1,1,LY gained,1837,1837,0,5193,Cost-effective,Cost-effective,0.35,1.89,Cost-effective,1.17,Cost-effective,0.671424489,Cost-effective,0.166700172,Not cost-effective,1.323739634,Cost-effective,0.548639884,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Government
35,3,3503,Castañeda-Orjuela,2012,"Cost-effectiveness of pneumococcal conjugate vaccines of 7, ",Colombia,Upper-middle,0,PCV13,PCV10,PCV13 vs PCV10,Three,1,Societal,US dollar,United States,2009,16.3,16.3,14.85,14.9,0,0,1,1,1,LY gained,9516,9516,0,5193,Not cost-effective,Cost-effective,1.83,1.89,Cost-effective,1.17,Not cost-effective,0.671424489,Not cost-effective,0.166700172,Not cost-effective,1.323739634,Not cost-effective,0.548639884,Not cost-effective,One GDPpc,Cost-effective,0,1,1,1,1,1,5,0,Government
36,1,3601,Gomez,2013,Cost-effectiveness and cost utility analysis of three pneumo,Peru,Upper-middle,0,PCV7,NoVax,PCV7 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2009,20,20,,,0,0,1,1,1,QALY gained,6014,6014,0,4196,Not cost-effective,Cost-effective,1.43,1.08,Not cost-effective,0.64,Not cost-effective,0.648684361,Not cost-effective,0.164872092,Not cost-effective,0.884510957,Not cost-effective,0.36655409,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Industry
36,2,3602,Gomez,2013,Cost-effectiveness and cost utility analysis of three pneumo,Peru,Upper-middle,0,PCV13,NoVax,PCV13 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2009,16.3,16.3,,,0,0,1,1,1,QALY gained,5327,5327,0,4196,Not cost-effective,Cost-effective,1.27,1.08,Not cost-effective,0.64,Not cost-effective,0.648684361,Not cost-effective,0.164872092,Not cost-effective,0.884510957,Not cost-effective,0.36655409,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Industry
36,3,3603,Gomez,2013,Cost-effectiveness and cost utility analysis of three pneumo,Peru,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2009,14.2,14.2,,,0,0,1,1,1,QALY gained,4500,4500,0,4196,Not cost-effective,Cost-effective,1.07,1.08,Cost-effective,0.64,Not cost-effective,0.648684361,Not cost-effective,0.164872092,Not cost-effective,0.884510957,Not cost-effective,0.36655409,Not cost-effective,Three GDPpc,Cost-effective,0,1,1,1,1,1,5,0,Industry
36,4,3604,Gomez,2013,Cost-effectiveness and cost utility analysis of three pneumo,Peru,Upper-middle,0,PCV10,PCV7,Others,Three,1,Healthcare/payer,US dollar,United States,2009,14.2,14.2,20,20,0,0,1,1,1,QALY gained,-2727,-2727,1,4196,Cost-saving,Cost-saving,-0.65,1.08,Cost-saving,0.64,Cost-saving,0.648684361,Cost-saving,0.164872092,Cost-saving,0.884510957,Cost-saving,0.36655409,Cost-saving,Three GDPpc,Cost-saving,,,,,,,0,0,Industry
36,5,3605,Gomez,2013,Cost-effectiveness and cost utility analysis of three pneumo,Peru,Upper-middle,0,PCV13,PCV7,Others,Three,1,Healthcare/payer,US dollar,United States,2009,16.3,16.3,20,20,0,0,1,1,1,QALY gained,999999,999999,0,4196,Not cost-effective,Not cost-effective,238.3,1.08,Not cost-effective,0.64,Not cost-effective,0.648684361,Not cost-effective,0.164872092,Not cost-effective,0.884510957,Not cost-effective,0.36655409,Not cost-effective,Three GDPpc,Not cost-effective,,,,,,,0,0,Industry
37,1,3701,Kieninger,2015,Cost-effectiveness analysis of pneumococcal conjugate vaccin,Paraguay,Lower-middle,0,PCV10,NoVax,PCV10 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2009,14.9,14.9,,,0,0,1,1,1,DALY averted,3851,3851,0,3627,Not cost-effective,Cost-effective,1.06,1.42,Cost-effective,0.83,Not cost-effective,0.367021867,Not cost-effective,0.081522985,Not cost-effective,1.19904181,Cost-effective,0.496937043,Not cost-effective,Three GDPpc,Cost-effective,0,1,1,1,0,1,4,1,Non-profit
37,2,3702,Kieninger,2015,Cost-effectiveness analysis of pneumococcal conjugate vaccin,Paraguay,Lower-middle,0,PCV10,NoVax,PCV10 vs NoVax,Three,0,Societal,US dollar,United States,2009,14.9,14.9,,,0,0,1,1,1,DALY averted,1920,1920,0,3627,Cost-effective,Cost-effective,0.53,1.42,Cost-effective,0.83,Cost-effective,0.367021867,Not cost-effective,0.081522985,Not cost-effective,1.19904181,Cost-effective,0.496937043,Not cost-effective,Three GDPpc,Cost-effective,0,0,1,1,0,1,3,1,Non-profit
37,3,3703,Kieninger,2015,Cost-effectiveness analysis of pneumococcal conjugate vaccin,Paraguay,Lower-middle,0,PCV13,NoVax,PCV13 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2009,20,20,,,0,0,1,1,1,DALY averted,4901,4901,0,3627,Not cost-effective,Cost-effective,1.35,1.42,Cost-effective,0.83,Not cost-effective,0.367021867,Not cost-effective,0.081522985,Not cost-effective,1.19904181,Not cost-effective,0.496937043,Not cost-effective,Three GDPpc,Cost-effective,0,1,1,1,1,1,5,1,Non-profit
37,4,3704,Kieninger,2015,Cost-effectiveness analysis of pneumococcal conjugate vaccin,Paraguay,Lower-middle,0,PCV13,NoVax,PCV13 vs NoVax,Three,0,Societal,US dollar,United States,2009,20,20,,,0,0,1,1,1,DALY averted,3657,3657,0,3627,Not cost-effective,Cost-effective,1.01,1.42,Cost-effective,0.83,Not cost-effective,0.367021867,Not cost-effective,0.081522985,Not cost-effective,1.19904181,Cost-effective,0.496937043,Not cost-effective,Three GDPpc,Cost-effective,0,1,1,1,0,1,4,1,Non-profit
37,5,3705,Kieninger,2015,Cost-effectiveness analysis of pneumococcal conjugate vaccin,Paraguay,Lower-middle,0,PCV13,PCV10,PCV13 vs PCV10,Three,1,Healthcare/payer,US dollar,United States,2009,20,20,14.85,14.9,0,0,1,1,1,DALY averted,12181,12181,0,3627,Not cost-effective,Not cost-effective,3.36,1.42,Not cost-effective,0.83,Not cost-effective,0.367021867,Not cost-effective,0.081522985,Not cost-effective,1.19904181,Not cost-effective,0.496937043,Not cost-effective,Three GDPpc,Not cost-effective,,,,,,,0,1,Non-profit
37,6,3706,Kieninger,2015,Cost-effectiveness analysis of pneumococcal conjugate vaccin,Paraguay,Lower-middle,0,PCV13,PCV10,PCV13 vs PCV10,Three,0,Societal,US dollar,United States,2009,20,20,14.85,14.9,0,0,1,1,1,DALY averted,3851,3851,0,3627,Not cost-effective,Cost-effective,1.06,1.42,Cost-effective,0.83,Not cost-effective,0.367021867,Not cost-effective,0.081522985,Not cost-effective,1.19904181,Cost-effective,0.496937043,Not cost-effective,Three GDPpc,Cost-effective,0,1,1,1,0,1,4,1,Non-profit
38,1,3801,Komakhidze,2015,Cost-effectiveness of pneumococcal conjugate vaccination in ,Georgia,Lower-middle,0,PCV10,NoVax,PCV10 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2012,3.5,3.5,,,1,1,1,1,1,DALY averted,1599,1599,0,4422,Cost-effective,Cost-effective,0.36,0.27,Not cost-effective,0.2,Not cost-effective,0.400108507,Cost-effective,0.079156602,Not cost-effective,1.033634929,Cost-effective,0.428268838,Cost-effective,One/Three GPDpc,Cost-effective,1,1,0,1,0,0,3,0,Non-profit
38,2,3802,Komakhidze,2015,Cost-effectiveness of pneumococcal conjugate vaccination in ,Georgia,Lower-middle,0,PCV10,NoVax,PCV10 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2012,3.5,3.5,,,0,1,1,1,1,QALY gained,2200,2200,0,4422,Cost-effective,Cost-effective,0.5,0.27,Not cost-effective,0.2,Not cost-effective,0.400108507,Not cost-effective,0.079156602,Not cost-effective,1.033634929,Cost-effective,0.428268838,Not cost-effective,One/Three GPDpc,Cost-effective,1,1,1,1,0,1,5,0,Non-profit
39,1,3901,Ordóñez,2015,Cost-effectiveness analysis of the available pneumococcal co,Colombia,Upper-middle,0,PCV13,NoVax,PCV13 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2013,15.7,15.7,,,0,0,1,1,1,LY gained,489,489,0,8218,Cost-effective,Cost-effective,0.06,1.89,Cost-effective,1.17,Cost-effective,0.671424489,Cost-effective,0.166700172,Cost-effective,1.323739634,Cost-effective,0.548639884,Cost-effective,One/Three GPDpc,Cost-effective,0,0,0,0,0,0,0,0,Industry
39,2,3902,Ordóñez,2015,Cost-effectiveness analysis of the available pneumococcal co,Colombia,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2013,14.1,14.1,,,0,0,1,1,1,LY gained,813,813,0,8218,Cost-effective,Cost-effective,0.1,1.89,Cost-effective,1.17,Cost-effective,0.671424489,Cost-effective,0.166700172,Cost-effective,1.323739634,Cost-effective,0.548639884,Cost-effective,One/Three GPDpc,Cost-effective,0,0,0,0,0,0,0,0,Industry
39,3,3903,Ordóñez,2015,Cost-effectiveness analysis of the available pneumococcal co,Colombia,Upper-middle,0,PCV13,PCV10,PCV13 vs PCV10,Four,1,Healthcare/payer,US dollar,United States,2013,15.7,15.7,14.12,14.1,0,0,1,1,1,LY gained,-418,-418,1,8218,Cost-saving,Cost-saving,-0.05,1.89,Cost-saving,1.17,Cost-saving,0.671424489,Cost-saving,0.166700172,Cost-saving,1.323739634,Cost-saving,0.548639884,Cost-saving,One GDPpc,Cost-saving,,,,,,,0,0,Industry
40,1,4001,Sartori,2010,Cost-effectiveness of introducing the 10-valent pneumococcal,Brazil,Lower-middle,0,PCV10,NoVax,PCV10 vs NoVax,Three,1,Societal,Brazilian real,Brazil,2004,31,10.6,,,0,0,1,1,1,DALY averted,22066,7544,0,3637,Not cost-effective,Cost-effective,2.07,1.09,Not cost-effective,0.71,Not cost-effective,0.613314051,Not cost-effective,0.194546729,Not cost-effective,1.673943393,Not cost-effective,0.693786261,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Government
40,2,4002,Sartori,2010,Cost-effectiveness of introducing the 10-valent pneumococcal,Brazil,Lower-middle,0,PCV10,NoVax,PCV10 vs NoVax,Three,0,Healthcare/payer,Brazilian real,Brazil,2004,31,10.6,,,0,0,1,1,1,DALY averted,24930,8523,0,3637,Not cost-effective,Cost-effective,2.34,1.09,Not cost-effective,0.71,Not cost-effective,0.613314051,Not cost-effective,0.194546729,Not cost-effective,1.673943393,Not cost-effective,0.693786261,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Government
41,1,4101,Türel,2013,Potential cost-effectiveness of pneumococcal conjugate vacci,Turkey,Upper-middle,0,PCV7,NoVax,PCV7 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2011,30,30,,,0,0,1,1,1,LY gained,7109,7109,0,11421,Cost-effective,Cost-effective,0.62,1.43,Cost-effective,0.82,Cost-effective,0.543885753,Not cost-effective,0.233852641,Not cost-effective,0.760180724,Cost-effective,0.315079233,Not cost-effective,One GDPpc,Cost-effective,0,0,1,1,0,1,3,0,Non-profit
41,2,4102,Türel,2013,Potential cost-effectiveness of pneumococcal conjugate vacci,Turkey,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2011,30,30,,,0,0,1,1,1,LY gained,6784,6784,0,11421,Cost-effective,Cost-effective,0.59,1.43,Cost-effective,0.82,Cost-effective,0.543885753,Not cost-effective,0.233852641,Not cost-effective,0.760180724,Cost-effective,0.315079233,Not cost-effective,One GDPpc,Cost-effective,0,0,1,1,0,1,3,0,Non-profit
41,3,4103,Türel,2013,Potential cost-effectiveness of pneumococcal conjugate vacci,Turkey,Upper-middle,0,PCV13,NoVax,PCV13 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2011,30,30,,,0,0,1,1,1,LY gained,6696,6696,0,11421,Cost-effective,Cost-effective,0.59,1.43,Cost-effective,0.82,Cost-effective,0.543885753,Not cost-effective,0.233852641,Not cost-effective,0.760180724,Cost-effective,0.315079233,Not cost-effective,One GDPpc,Cost-effective,0,0,1,1,0,1,3,0,Non-profit
42,1,4201,Guzmán,2010,Cost effectiveness of heptavalent pneumococcal conjugate vac,Colombia,Lower-middle,0,PCV7,NoVax,PCV7 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2006,35,35,,,0,0,1,1,1,LY gained,752,752,0,3741,Cost-effective,Cost-effective,0.2,1.89,Cost-effective,1.17,Cost-effective,0.671424489,Cost-effective,0.166700172,Not cost-effective,1.323739634,Cost-effective,0.548639884,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Non-profit
43,1,4301,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Argentina,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2009,20,20,,,0,0,1,1,1,QALY gained,3348,3348,0,8225,Cost-effective,Cost-effective,0.41,0.56,Cost-effective,0.37,Not cost-effective,,NA,,NA,1.63265299,Cost-effective,0.676667495,Cost-effective,Three GDPpc,Cost-effective,0,1,0,0,0,0,1,0,Industry
43,2,4302,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Argentina,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,0,Societal,US dollar,United States,2009,20,20,,,0,0,1,1,1,QALY gained,1510,1510,0,8225,Cost-effective,Cost-effective,0.18,0.56,Cost-effective,0.37,Cost-effective,,NA,,NA,1.63265299,Cost-effective,0.676667495,Cost-effective,Three GDPpc,Cost-effective,0,0,0,0,0,0,0,0,Industry
43,3,4303,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Argentina,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,0,Healthcare/payer,US dollar,United States,2009,20,20,,,1,0,1,1,1,QALY gained,3295,3295,0,8225,Cost-effective,Cost-effective,0.4,0.56,Cost-effective,0.37,Not cost-effective,,NA,,NA,1.63265299,Cost-effective,0.676667495,Cost-effective,Three GDPpc,Cost-effective,0,1,0,0,0,0,1,0,Industry
43,4,4304,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Argentina,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,0,Healthcare/payer,US dollar,United States,2009,20,20,,,1,1,1,1,1,QALY gained,1455,1455,0,8225,Cost-effective,Cost-effective,0.18,0.56,Cost-effective,0.37,Cost-effective,,NA,,NA,1.63265299,Cost-effective,0.676667495,Cost-effective,Three GDPpc,Cost-effective,0,0,0,0,0,0,0,0,Industry
43,5,4305,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Brazil,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2008,20,20,,,0,0,1,1,1,QALY gained,7089,7089,0,8831,Cost-effective,Cost-effective,0.8,1.09,Cost-effective,0.71,Not cost-effective,0.613314051,Not cost-effective,0.194546729,Not cost-effective,1.673943393,Cost-effective,0.693786261,Not cost-effective,Three GDPpc,Cost-effective,0,1,1,1,0,1,4,0,Industry
43,6,4306,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Brazil,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,0,Societal,US dollar,United States,2008,20,20,,,0,0,1,1,1,QALY gained,4811,4811,0,8831,Cost-effective,Cost-effective,0.54,1.09,Cost-effective,0.71,Cost-effective,0.613314051,Cost-effective,0.194546729,Not cost-effective,1.673943393,Cost-effective,0.693786261,Cost-effective,Three GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Industry
43,7,4307,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Brazil,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,0,Healthcare/payer,US dollar,United States,2008,20,20,,,1,0,1,1,1,QALY gained,6293,6293,0,8831,Cost-effective,Cost-effective,0.71,1.09,Cost-effective,0.71,Not cost-effective,0.613314051,Not cost-effective,0.194546729,Not cost-effective,1.673943393,Cost-effective,0.693786261,Not cost-effective,Three GDPpc,Cost-effective,0,1,1,1,0,1,4,0,Industry
43,8,4308,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Brazil,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,0,Healthcare/payer,US dollar,United States,2008,20,20,,,1,1,1,1,1,QALY gained,4025,4025,0,8831,Cost-effective,Cost-effective,0.46,1.09,Cost-effective,0.71,Cost-effective,0.613314051,Cost-effective,0.194546729,Not cost-effective,1.673943393,Cost-effective,0.693786261,Cost-effective,Three GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Industry
43,9,4309,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Colombia,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2008,20,20,,,0,0,1,1,1,QALY gained,4021,4021,0,5473,Cost-effective,Cost-effective,0.73,1.89,Cost-effective,1.17,Cost-effective,0.671424489,Not cost-effective,0.166700172,Not cost-effective,1.323739634,Cost-effective,0.548639884,Not cost-effective,Three GDPpc,Cost-effective,0,0,1,1,0,1,3,0,Industry
43,10,4310,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Colombia,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,0,Societal,US dollar,United States,2008,20,20,,,0,0,1,1,1,QALY gained,2433,2433,0,5473,Cost-effective,Cost-effective,0.44,1.89,Cost-effective,1.17,Cost-effective,0.671424489,Cost-effective,0.166700172,Not cost-effective,1.323739634,Cost-effective,0.548639884,Cost-effective,Three GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Industry
43,11,4311,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Colombia,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,0,Healthcare/payer,US dollar,United States,2008,20,20,,,1,0,1,1,1,QALY gained,3886,3886,0,5473,Cost-effective,Cost-effective,0.71,1.89,Cost-effective,1.17,Cost-effective,0.671424489,Not cost-effective,0.166700172,Not cost-effective,1.323739634,Cost-effective,0.548639884,Not cost-effective,Three GDPpc,Cost-effective,0,0,1,1,0,1,3,0,Industry
43,12,4312,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Colombia,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,0,Healthcare/payer,US dollar,United States,2008,20,20,,,1,1,1,1,1,QALY gained,2296,2296,0,5473,Cost-effective,Cost-effective,0.42,1.89,Cost-effective,1.17,Cost-effective,0.671424489,Cost-effective,0.166700172,Not cost-effective,1.323739634,Cost-effective,0.548639884,Cost-effective,Three GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Industry
43,13,4313,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Mexico,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2008,20,20,,,0,0,1,1,1,QALY gained,4594,4594,0,10017,Cost-effective,Cost-effective,0.46,0.97,Cost-effective,0.64,Cost-effective,0.629266618,Cost-effective,0.224704778,Not cost-effective,0.922169342,Cost-effective,0.382193767,Not cost-effective,Three GDPpc,Cost-effective,0,0,0,1,0,1,2,0,Industry
43,14,4314,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Mexico,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,0,Societal,US dollar,United States,2008,20,20,,,0,0,1,1,1,QALY gained,3243,3243,0,10017,Cost-effective,Cost-effective,0.32,0.97,Cost-effective,0.64,Cost-effective,0.629266618,Cost-effective,0.224704778,Not cost-effective,0.922169342,Cost-effective,0.382193767,Cost-effective,Three GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Industry
43,15,4315,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Mexico,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,0,Healthcare/payer,US dollar,United States,2008,20,20,,,1,0,1,1,1,QALY gained,4144,4144,0,10017,Cost-effective,Cost-effective,0.41,0.97,Cost-effective,0.64,Cost-effective,0.629266618,Cost-effective,0.224704778,Not cost-effective,0.922169342,Cost-effective,0.382193767,Not cost-effective,Three GDPpc,Cost-effective,0,0,0,1,0,1,2,0,Industry
43,16,4316,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Mexico,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,0,Healthcare/payer,US dollar,United States,2008,20,20,,,1,1,1,1,1,QALY gained,2791,2791,0,10017,Cost-effective,Cost-effective,0.28,0.97,Cost-effective,0.64,Cost-effective,0.629266618,Cost-effective,0.224704778,Not cost-effective,0.922169342,Cost-effective,0.382193767,Cost-effective,Three GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Industry
43,17,4317,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Peru,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,1,Healthcare/payer,US dollar,United States,2009,20,20,,,0,0,1,1,1,QALY gained,2975,2975,0,4196,Cost-effective,Cost-effective,0.71,1.08,Cost-effective,0.64,Not cost-effective,0.648684361,Not cost-effective,0.164872092,Not cost-effective,0.884510957,Cost-effective,0.36655409,Not cost-effective,Three GDPpc,Cost-effective,0,1,1,1,0,1,4,0,Industry
43,18,4318,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Peru,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,0,Societal,US dollar,United States,2009,20,20,,,0,0,1,1,1,QALY gained,1536,1536,0,4196,Cost-effective,Cost-effective,0.37,1.08,Cost-effective,0.64,Cost-effective,0.648684361,Cost-effective,0.164872092,Not cost-effective,0.884510957,Cost-effective,0.36655409,Cost-effective,Three GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Industry
43,19,4319,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Peru,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,0,Healthcare/payer,US dollar,United States,2009,20,20,,,1,0,1,1,1,QALY gained,2921,2921,0,4196,Cost-effective,Cost-effective,0.7,1.08,Cost-effective,0.64,Not cost-effective,0.648684361,Not cost-effective,0.164872092,Not cost-effective,0.884510957,Cost-effective,0.36655409,Not cost-effective,Three GDPpc,Cost-effective,0,1,1,1,0,1,4,0,Industry
43,20,4320,Marti,2013,A cost-effectiveness analysis of a 10-valent pneumococcal co,Peru,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Four,0,Healthcare/payer,US dollar,United States,2009,20,20,,,1,1,1,1,1,QALY gained,1479,1479,0,4196,Cost-effective,Cost-effective,0.35,1.08,Cost-effective,0.64,Cost-effective,0.648684361,Cost-effective,0.164872092,Not cost-effective,0.884510957,Cost-effective,0.36655409,Cost-effective,Three GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Industry
44,1,4401,Giglio,2010,Cost-effectiveness of the CRM-based 7-valent pneumococcal co,Argentina,Upper-middle,0,PCV7,NoVax,PCV7 vs NoVax,Four,1,Societal,US dollar,United States,2007,26.5,26.5,,,0,0,1,1,1,LY gained,5599,5599,0,7245,Cost-effective,Cost-effective,0.77,0.56,Not cost-effective,0.37,Not cost-effective,,NA,,NA,1.63265299,Cost-effective,0.676667495,Not cost-effective,One/Three GPDpc,Cost-effective,1,1,0,0,0,1,3,1,Industry
44,2,4402,Giglio,2010,Cost-effectiveness of the CRM-based 7-valent pneumococcal co,Argentina,Upper-middle,0,PCV7,NoVax,PCV7 vs NoVax,Four,0,Societal,US dollar,United States,2007,26.5,26.5,,,1,0,1,1,1,LY gained,2822,2822,0,7245,Cost-effective,Cost-effective,0.39,0.56,Cost-effective,0.37,Not cost-effective,,NA,,NA,1.63265299,Cost-effective,0.676667495,Cost-effective,One/Three GPDpc,Cost-effective,0,1,0,0,0,0,1,1,Industry
44,3,4403,Giglio,2010,Cost-effectiveness of the CRM-based 7-valent pneumococcal co,Argentina,Upper-middle,0,PCV7,NoVax,PCV7 vs NoVax,Four,0,Healthcare/payer,US dollar,United States,2007,26.5,26.5,,,0,0,1,1,1,LY gained,5828,5828,0,7245,Cost-effective,Cost-effective,0.8,0.56,Not cost-effective,0.37,Not cost-effective,,NA,,NA,1.63265299,Cost-effective,0.676667495,Not cost-effective,One/Three GPDpc,Cost-effective,1,1,0,0,0,1,3,1,Industry
45,1,4501,Talbird,2010,"Outcomes and costs associated with PHiD-CV, a new protein D ",Mexico,Upper-middle,0,PCV10,PCV7,Others,Three,1,Healthcare/payer,Mexican peso,Mexico,2008,,,,,0,1,1,1,1,QALY gained,-70783,-6360,1,10017,Cost-saving,Cost-saving,-0.63,0.97,Cost-saving,0.64,Cost-saving,0.629266618,Cost-saving,0.224704778,Cost-saving,0.922169342,Cost-saving,0.382193767,Cost-saving,One/Three GPDpc,Cost-saving,,,,,,,0,0,Industry
45,2,4502,Talbird,2010,"Outcomes and costs associated with PHiD-CV, a new protein D ",Mexico,Upper-middle,0,PCV10,PCV7,Others,Three,1,Healthcare/payer,Mexican peso,Mexico,2008,,,,,1,1,1,1,1,QALY gained,-999999,-999999,1,10017,Cost-saving,Cost-saving,-99.83,0.97,Cost-saving,0.64,Cost-saving,0.629266618,Cost-saving,0.224704778,Cost-saving,0.922169342,Cost-saving,0.382193767,Cost-saving,One/Three GPDpc,Cost-saving,,,,,,,0,0,Industry
46,1,4601,Constenla,2015,Post-introduction economic evaluation of pneumococcal conjug,Ecuador,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Unknown,1,Societal,US dollar,United States,2014,14.1,14.1,,,0,0,1,1,1,QALY gained,1340,730,0,6377,Cost-effective,Cost-effective,0.11,1.12,Cost-effective,0.72,Cost-effective,0.526886639,Cost-effective,0.141669927,Cost-effective,1.342220476,Cost-effective,0.556205109,Cost-effective,One/Three GPDpc,Cost-effective,0,0,0,0,0,0,0,0,Non-profit
46,2,4602,Constenla,2015,Post-introduction economic evaluation of pneumococcal conjug,Ecuador,Upper-middle,0,PCV13,NoVax,PCV13 vs NoVax,Unknown,1,Societal,US dollar,United States,2014,15.7,15.7,,,0,0,1,1,1,QALY gained,1166,635,0,6377,Cost-effective,Cost-effective,0.1,1.12,Cost-effective,0.72,Cost-effective,0.526886639,Cost-effective,0.141669927,Cost-effective,1.342220476,Cost-effective,0.556205109,Cost-effective,One/Three GPDpc,Cost-effective,0,0,0,0,0,0,0,0,Non-profit
46,3,4603,Constenla,2015,Post-introduction economic evaluation of pneumococcal conjug,Honduras,Lower-middle,0,PCV10,NoVax,PCV10 vs NoVax,Unknown,1,Societal,US dollar,United States,2014,14.1,14.1,,,0,0,1,1,1,QALY gained,796,394,0,2191,Cost-effective,Cost-effective,0.18,1,Cost-effective,0.68,Cost-effective,0.563671077,Cost-effective,0.071356831,Not cost-effective,0.79524126,Cost-effective,0.320365269,Cost-effective,One/Three GPDpc,Cost-effective,0,0,0,1,0,0,1,0,Non-profit
46,4,4604,Constenla,2015,Post-introduction economic evaluation of pneumococcal conjug,Honduras,Lower-middle,0,PCV13,NoVax,PCV13 vs NoVax,Unknown,1,Societal,US dollar,United States,2014,15.7,15.7,,,0,0,1,1,1,QALY gained,691,342,0,2191,Cost-effective,Cost-effective,0.16,1,Cost-effective,0.68,Cost-effective,0.563671077,Cost-effective,0.071356831,Not cost-effective,0.79524126,Cost-effective,0.320365269,Cost-effective,One/Three GPDpc,Cost-effective,0,0,0,1,0,0,1,0,Non-profit
46,5,4605,Constenla,2015,Post-introduction economic evaluation of pneumococcal conjug,Paraguay,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Unknown,1,Societal,US dollar,United States,2014,14.1,14.1,,,0,0,1,1,1,QALY gained,1226,655,0,6118,Cost-effective,Cost-effective,0.11,1.42,Cost-effective,0.83,Cost-effective,0.367021867,Cost-effective,0.081522985,Not cost-effective,1.19904181,Cost-effective,0.496937043,Cost-effective,One/Three GPDpc,Cost-effective,0,0,0,1,0,0,1,0,Non-profit
46,6,4606,Constenla,2015,Post-introduction economic evaluation of pneumococcal conjug,Paraguay,Upper-middle,0,PCV13,NoVax,PCV13 vs NoVax,Unknown,1,Societal,US dollar,United States,2014,15.7,15.7,,,0,0,1,1,1,QALY gained,1026,548,0,6118,Cost-effective,Cost-effective,0.09,1.42,Cost-effective,0.83,Cost-effective,0.367021867,Cost-effective,0.081522985,Not cost-effective,1.19904181,Cost-effective,0.496937043,Cost-effective,One/Three GPDpc,Cost-effective,0,0,0,1,0,0,1,0,Non-profit
47,1,4701,Castaneda-Orjuela,2018,How cost effective is switching universal vaccination from P,Colombia,Upper-middle,0,PCV13,NoVax,PCV13 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2014,15.7,15.7,,,0,0,1,1,1,LY gained,2319,2319,0,8114,Cost-effective,Cost-effective,0.29,1.89,Cost-effective,1.17,Cost-effective,0.671424489,Cost-effective,0.166700172,Not cost-effective,1.323739634,Cost-effective,0.548639884,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Non-profit
47,2,4702,Castaneda-Orjuela,2018,How cost effective is switching universal vaccination from P,Colombia,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2014,14.1,14.1,,,0,0,1,1,1,LY gained,1770,1770,0,8114,Cost-effective,Cost-effective,0.22,1.89,Cost-effective,1.17,Cost-effective,0.671424489,Cost-effective,0.166700172,Not cost-effective,1.323739634,Cost-effective,0.548639884,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Non-profit
47,3,4703,Castaneda-Orjuela,2018,How cost effective is switching universal vaccination from P,Colombia,Upper-middle,0,PCV13,PCV10,PCV13 vs PCV10,Three,1,Healthcare/payer,US dollar,United States,2014,15.7,15.7,14.12,14.1,0,0,1,1,1,LY gained,2217,2217,0,8114,Cost-effective,Cost-effective,0.27,1.89,Cost-effective,1.17,Cost-effective,0.671424489,Cost-effective,0.166700172,Not cost-effective,1.323739634,Cost-effective,0.548639884,Cost-effective,One GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Non-profit
48,1,4801,Marijam,2019,Cost-Effectiveness Comparison of Pneumococcal Conjugate Vacc,Turkey,Upper-middle,0,PCV13,PCV10,PCV13 vs PCV10,Four,1,Healthcare/payer,Euro,Euro area,2016,23.8,26.3,,,0,0,1,1,1,QALY gained,999999,999999,0,10895,Not cost-effective,Not cost-effective,91.79,1.43,Not cost-effective,0.82,Not cost-effective,0.543885753,Not cost-effective,0.233852641,Not cost-effective,0.760180724,Not cost-effective,0.315079233,Not cost-effective,One GDPpc,Not cost-effective,,,,,,,0,0,Industry
49,1,4901,Pugh,2019,Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10,Tunisia,Lower-middle,0,PCV13,NoVax,PCV13 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2017,15.7,15.7,,,0,0,1,1,1,QALY gained,848,848,0,3688,Cost-effective,Cost-effective,0.23,1.22,Cost-effective,0.71,Cost-effective,0.583151181,Cost-effective,0.15253723,Not cost-effective,0.690975961,Cost-effective,0.278068869,Cost-effective,One/Three GPDpc,Cost-effective,0,0,0,1,0,0,1,0,Industry
49,2,4902,Pugh,2019,Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10,Tunisia,Lower-middle,0,PCV10,NoVax,PCV10 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2017,15.7,15.7,,,0,0,1,1,1,QALY gained,1366,1366,0,3688,Cost-effective,Cost-effective,0.37,1.22,Cost-effective,0.71,Cost-effective,0.583151181,Cost-effective,0.15253723,Not cost-effective,0.690975961,Cost-effective,0.278068869,Not cost-effective,One/Three GPDpc,Cost-effective,0,0,0,1,0,1,2,0,Industry
49,3,4903,Pugh,2019,Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10,Algeria,Upper-middle,0,PCV13,NoVax,PCV13 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2017,15.7,15.7,,,0,0,1,1,1,QALY gained,308,308,0,4110,Cost-effective,Cost-effective,0.07,1.54,Cost-effective,0.97,Cost-effective,0.68059652,Cost-effective,0.184013807,Cost-effective,0.667474039,Cost-effective,0.268694018,Cost-effective,One/Three GPDpc,Cost-effective,0,0,0,0,0,0,0,0,Industry
49,4,4904,Pugh,2019,Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10,Algeria,Upper-middle,0,PCV10,NoVax,PCV10 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2017,15.7,15.7,,,0,0,1,1,1,QALY gained,731,731,0,4110,Cost-effective,Cost-effective,0.18,1.54,Cost-effective,0.97,Cost-effective,0.68059652,Cost-effective,0.184013807,Cost-effective,0.667474039,Cost-effective,0.268694018,Cost-effective,One/Three GPDpc,Cost-effective,0,0,0,0,0,0,0,0,Industry
50,1,5001,Pugh,2020,Estimating the Impact of Switching from a Lower to Higher Va,Colombia,Upper-middle,0,PCV13,PCV10,PCV13 vs PCV10,Three,1,Healthcare/payer,US dollar,United States,2016,14.8,14.8,12.85,12.9,1,0,1,1,1,QALY gained,-9341,-9341,1,5871,Cost-saving,Cost-saving,-1.59,1.89,Cost-saving,1.17,Cost-saving,0.671424489,Cost-saving,0.166700172,Cost-saving,1.323739634,Cost-saving,0.548639884,Cost-saving,One/Three GPDpc,Cost-saving,,,,,,,0,0,Industry
51,1,5101,Pecenka,2021,Pneumococcal conjugate vaccination in The Gambia: health imp,"Gambia, The",Low,0,PCV13,NoVax,PCV13 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2017,0.2,0.2,,,0,0,1,1,0,DALY averted,-999999,-999999,1,680,Cost-saving,Cost-saving,-1471.12,0.69,Cost-saving,0.52,Cost-saving,0.359734802,Cost-saving,0.017130229,Cost-saving,0.255166171,Cost-saving,0.05051513,Cost-saving,NA,Cost-saving,,,,,,,0,1,Mixed
51,2,5102,Pecenka,2021,Pneumococcal conjugate vaccination in The Gambia: health imp,"Gambia, The",Low,0,PCV13,NoVax,PCV13 vs NoVax,Three,1,Societal,US dollar,United States,2017,0.2,0.2,,,0,0,1,1,0,DALY averted,-999999,-999999,1,680,Cost-saving,Cost-saving,-1471.12,0.69,Cost-saving,0.52,Cost-saving,0.359734802,Cost-saving,0.017130229,Cost-saving,0.255166171,Cost-saving,0.05051513,Cost-saving,NA,Cost-saving,,,,,,,0,1,Mixed
52,1,5201,Perdrizet,2021,Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate V,Philippines,Lower-middle,1,PCV13,PCV10,PCV13 vs PCV10,Three,1,Societal,Philippine peso,Philippines,2019,704.4,13.6,624.27,12.1,1,1,1,1,1,QALY gained,-80045,-1545,1,3485,Cost-saving,Cost-saving,-0.44,0.34,Cost-saving,0.23,Cost-saving,0.494875427,Cost-saving,0.089154194,Cost-saving,0.401969294,Cost-saving,0.161820615,Cost-saving,"PHP 150,000",Cost-saving,,,,,,,0,0,Industry
52,2,5202,Perdrizet,2021,Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate V,Philippines,Lower-middle,1,PCV13,PCV10,PCV13 vs PCV10,Three,1,Societal,Philippine peso,Philippines,2019,704.4,13.6,624.27,12.1,1,1,1,1,1,QALY gained,-39466,-762,1,3485,Cost-saving,Cost-saving,-0.22,0.34,Cost-saving,0.23,Cost-saving,0.494875427,Cost-saving,0.089154194,Cost-saving,0.401969294,Cost-saving,0.161820615,Cost-saving,"PHP 150,000",Cost-saving,,,,,,,0,0,Industry
53,1,5301,Perdrizet,2021,Cost-effectiveness analysis of replacing the 10-valent pneum,Brazil,Upper-middle,0,PCV13,PCV10,PCV13 vs PCV10,Three,1,Healthcare/payer,Brazilian real,Brazil,2019,58.9,14.9,57.22,14.5,1,1,1,1,1,QALY gained,-8471,-2148,1,8898,Cost-saving,Cost-saving,-0.24,1.09,Cost-saving,0.71,Cost-saving,0.613314051,Cost-saving,0.194546729,Cost-saving,1.673943393,Cost-saving,0.693786261,Cost-saving,One GDPpc,Cost-saving,,,,,,,0,0,Industry
54,1,5401,Suwantika,2021,Cost-Effectiveness and Budget Impact Analyses of Pneumococca,Indonesia,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2019,3.1,3.1,,,0,0,1,1,0,QALY gained,162,162,0,4135,Cost-effective,Cost-effective,0.04,0.23,Cost-effective,0.16,Cost-effective,0.492835502,Cost-effective,0.130245441,Cost-effective,0.471561056,Cost-effective,0.195395555,Cost-effective,One/Three GPDpc,Cost-effective,0,0,0,0,0,0,0,1,Non-profit
54,2,5402,Suwantika,2021,Cost-Effectiveness and Budget Impact Analyses of Pneumococca,Indonesia,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,1,Societal,US dollar,United States,2019,3.1,3.1,,,0,0,1,1,0,QALY gained,254,254,0,4135,Cost-effective,Cost-effective,0.06,0.23,Cost-effective,0.16,Cost-effective,0.492835502,Cost-effective,0.130245441,Cost-effective,0.471561056,Cost-effective,0.195395555,Cost-effective,One/Three GPDpc,Cost-effective,0,0,0,0,0,0,0,1,Non-profit
54,3,5403,Suwantika,2021,Cost-Effectiveness and Budget Impact Analyses of Pneumococca,Indonesia,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2019,3.1,3.1,,,0,0,1,1,0,QALY gained,322,322,0,4135,Cost-effective,Cost-effective,0.08,0.23,Cost-effective,0.16,Cost-effective,0.492835502,Cost-effective,0.130245441,Cost-effective,0.471561056,Cost-effective,0.195395555,Cost-effective,One/Three GPDpc,Cost-effective,0,0,0,0,0,0,0,1,Non-profit
54,4,5404,Suwantika,2021,Cost-Effectiveness and Budget Impact Analyses of Pneumococca,Indonesia,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2019,18.9,18.9,,,0,0,1,1,0,QALY gained,447,447,0,4135,Cost-effective,Cost-effective,0.11,0.23,Cost-effective,0.16,Cost-effective,0.492835502,Cost-effective,0.130245441,Cost-effective,0.471561056,Cost-effective,0.195395555,Cost-effective,One/Three GPDpc,Cost-effective,0,0,0,0,0,0,0,1,Non-profit
54,5,5405,Suwantika,2021,Cost-Effectiveness and Budget Impact Analyses of Pneumococca,Indonesia,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,1,Societal,US dollar,United States,2019,18.9,18.9,,,0,0,1,1,0,QALY gained,539,539,0,4135,Cost-effective,Cost-effective,0.13,0.23,Cost-effective,0.16,Cost-effective,0.492835502,Cost-effective,0.130245441,Not cost-effective,0.471561056,Cost-effective,0.195395555,Cost-effective,One/Three GPDpc,Cost-effective,0,0,0,1,0,0,1,1,Non-profit
54,6,5406,Suwantika,2021,Cost-Effectiveness and Budget Impact Analyses of Pneumococca,Indonesia,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2019,18.9,18.9,,,0,0,1,1,0,QALY gained,607,607,0,4135,Cost-effective,Cost-effective,0.15,0.23,Cost-effective,0.16,Cost-effective,0.492835502,Cost-effective,0.130245441,Not cost-effective,0.471561056,Cost-effective,0.195395555,Cost-effective,One/Three GPDpc,Cost-effective,0,0,0,1,0,0,1,1,Non-profit
54,7,5407,Suwantika,2021,Cost-Effectiveness and Budget Impact Analyses of Pneumococca,Indonesia,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2019,3.3,3.3,,,0,0,1,1,0,QALY gained,718,718,0,4135,Cost-effective,Cost-effective,0.17,0.23,Cost-effective,0.16,Not cost-effective,0.492835502,Cost-effective,0.130245441,Not cost-effective,0.471561056,Cost-effective,0.195395555,Cost-effective,One/Three GPDpc,Cost-effective,0,1,0,1,0,0,2,1,Non-profit
54,8,5408,Suwantika,2021,Cost-Effectiveness and Budget Impact Analyses of Pneumococca,Indonesia,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Three,1,Societal,US dollar,United States,2019,3.3,3.3,,,0,0,1,1,0,QALY gained,810,810,0,4135,Cost-effective,Cost-effective,0.2,0.23,Cost-effective,0.16,Not cost-effective,0.492835502,Cost-effective,0.130245441,Not cost-effective,0.471561056,Cost-effective,0.195395555,Not cost-effective,One/Three GPDpc,Cost-effective,0,1,0,1,0,1,3,1,Non-profit
54,9,5409,Suwantika,2021,Cost-Effectiveness and Budget Impact Analyses of Pneumococca,Indonesia,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2019,3.3,3.3,,,0,0,1,1,0,QALY gained,978,978,0,4135,Cost-effective,Cost-effective,0.24,0.23,Not cost-effective,0.16,Not cost-effective,0.492835502,Cost-effective,0.130245441,Not cost-effective,0.471561056,Cost-effective,0.195395555,Not cost-effective,One/Three GPDpc,Cost-effective,1,1,0,1,0,1,4,1,Non-profit
54,10,5410,Suwantika,2021,Cost-Effectiveness and Budget Impact Analyses of Pneumococca,Indonesia,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2019,17.5,17.5,,,0,0,1,1,0,QALY gained,1087,1087,0,4135,Cost-effective,Cost-effective,0.26,0.23,Not cost-effective,0.16,Not cost-effective,0.492835502,Cost-effective,0.130245441,Not cost-effective,0.471561056,Cost-effective,0.195395555,Not cost-effective,One/Three GPDpc,Cost-effective,1,1,0,1,0,1,4,1,Non-profit
54,11,5411,Suwantika,2021,Cost-Effectiveness and Budget Impact Analyses of Pneumococca,Indonesia,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Three,1,Societal,US dollar,United States,2019,17.5,17.5,,,0,0,1,1,0,QALY gained,1179,1179,0,4135,Cost-effective,Cost-effective,0.29,0.23,Not cost-effective,0.16,Not cost-effective,0.492835502,Cost-effective,0.130245441,Not cost-effective,0.471561056,Cost-effective,0.195395555,Not cost-effective,One/Three GPDpc,Cost-effective,1,1,0,1,0,1,4,1,Non-profit
54,12,5412,Suwantika,2021,Cost-Effectiveness and Budget Impact Analyses of Pneumococca,Indonesia,Upper-middle,1,PCV10,NoVax,PCV10 vs NoVax,Three,1,Healthcare/payer,US dollar,United States,2019,17.5,17.5,,,0,0,1,1,0,QALY gained,1248,1248,0,4135,Cost-effective,Cost-effective,0.3,0.23,Not cost-effective,0.16,Not cost-effective,0.492835502,Cost-effective,0.130245441,Not cost-effective,0.471561056,Cost-effective,0.195395555,Not cost-effective,One/Three GPDpc,Cost-effective,1,1,0,1,0,1,4,1,Non-profit
55,1,5501,Wang,2021,Cost-effectiveness analysis of domestic 13-valent pneumococc,China,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Four,1,Societal,US dollar,United States,2019,81,81,,,0,0,1,1,1,QALY gained,15394,15394,0,10144,Not cost-effective,Cost-effective,1.52,0.71,Not cost-effective,0.45,Not cost-effective,0.648116898,Not cost-effective,0.163952209,Not cost-effective,0.902715505,Not cost-effective,0.374118744,Not cost-effective,Three GDPpc,Cost-effective,1,1,1,1,1,1,6,0,Government
55,2,5502,Wang,2021,Cost-effectiveness analysis of domestic 13-valent pneumococc,China,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,1,Societal,US dollar,United States,2019,81,81,,,0,0,1,1,1,QALY gained,2292,2292,0,10144,Cost-effective,Cost-effective,0.23,0.71,Cost-effective,0.45,Cost-effective,0.648116898,Cost-effective,0.163952209,Not cost-effective,0.902715505,Cost-effective,0.374118744,Cost-effective,Three GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Government
55,3,5503,Wang,2021,Cost-effectiveness analysis of domestic 13-valent pneumococc,China,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,One/two,1,Societal,US dollar,United States,2019,81,81,,,0,0,1,1,1,QALY gained,3445,3445,0,10144,Cost-effective,Cost-effective,0.34,0.71,Cost-effective,0.45,Cost-effective,0.648116898,Cost-effective,0.163952209,Not cost-effective,0.902715505,Cost-effective,0.374118744,Cost-effective,Three GDPpc,Cost-effective,0,0,0,1,0,0,1,0,Government
55,4,5504,Wang,2021,Cost-effectiveness analysis of domestic 13-valent pneumococc,China,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,One/two,1,Societal,US dollar,United States,2019,81,81,,,0,0,1,1,1,QALY gained,4417,4417,0,10144,Cost-effective,Cost-effective,0.44,0.71,Cost-effective,0.45,Cost-effective,0.648116898,Cost-effective,0.163952209,Not cost-effective,0.902715505,Cost-effective,0.374118744,Not cost-effective,Three GDPpc,Cost-effective,0,0,0,1,0,1,2,0,Government
56,1,5601,Shafie,2020,Estimating the population health and economic impacts of int,Malaysia,Upper-middle,1,PCV13,PCV10,PCV13 vs PCV10,Three,1,Societal,US dollar,United States,2018,,,,,1,0,1,1,1,QALY gained,-39432,-39432,1,11380,Cost-saving,Cost-saving,-3.46,0.75,Cost-saving,0.45,Cost-saving,0.564443129,Cost-saving,0.317316947,Cost-saving,0.668688739,Cost-saving,0.277184384,Cost-saving,Three GDPpc,Cost-effective,0,0,0,0,0,0,0,0,Industry
56,2,5602,Shafie,2020,Estimating the population health and economic impacts of int,Malaysia,Upper-middle,1,PCV13,NoVax,PCV13 vs NoVax,Three,1,Societal,US dollar,United States,2018,,,,,1,0,1,1,1,QALY gained,-74631,-74631,1,11380,Cost-saving,Cost-saving,-6.56,0.75,Cost-saving,0.45,Cost-saving,0.564443129,Cost-saving,0.317316947,Cost-saving,0.668688739,Cost-saving,0.277184384,Cost-saving,Three GDPpc,Cost-effective,0,0,0,0,0,0,0,0,Industry
56,3,5603,Shafie,2020,Estimating the population health and economic impacts of int,Malaysia,Upper-middle,1,PCV13,PCV10,PCV13 vs PCV10,Three,0,Healthcare/payer,US dollar,United States,2018,,,,,1,0,1,1,1,QALY gained,-26536,-26536,1,11380,Cost-saving,Cost-saving,-2.33,0.75,Cost-saving,0.45,Cost-saving,0.564443129,Cost-saving,0.317316947,Cost-saving,0.668688739,Cost-saving,0.277184384,Cost-saving,Three GDPpc,Cost-effective,0,0,0,0,0,0,0,0,Industry
56,4,5604,Shafie,2020,Estimating the population health and economic impacts of int,Malaysia,Upper-middle,1,PCV13,PCV10,PCV13 vs PCV10,Three,0,Societal,US dollar,United States,2018,,,,,1,0,1,1,1,QALY gained,-72390,-72390,1,11380,Cost-saving,Cost-saving,-6.36,0.75,Cost-saving,0.45,Cost-saving,0.564443129,Cost-saving,0.317316947,Cost-saving,0.668688739,Cost-saving,0.277184384,Cost-saving,Three GDPpc,Cost-effective,0,0,0,0,0,0,0,0,Industry
56,5,5605,Shafie,2020,Estimating the population health and economic impacts of int,Malaysia,Upper-middle,1,PCV13,PCV10,PCV13 vs PCV10,Three,0,Societal,US dollar,United States,2018,,,,,1,0,1,1,1,QALY gained,-67680,-67680,1,11380,Cost-saving,Cost-saving,-5.95,0.75,Cost-saving,0.45,Cost-saving,0.564443129,Cost-saving,0.317316947,Cost-saving,0.668688739,Cost-saving,0.277184384,Cost-saving,Three GDPpc,Cost-effective,0,0,0,0,0,0,0,0,Industry
57,1,5701,Wasserman,2019,Modeling the sustained use of the 13-valent pneumococcal con,Mexico,Upper-middle,0,PCV13,PCV10,PCV13 vs PCV10,Three,1,Healthcare/payer,US dollar,United States,2018,12.9,12.9,14.5,14.5,1,1,1,1,1,QALY gained,-5134464,-266804,1,9687,Cost-saving,Cost-saving,-27.54,0.97,Cost-saving,0.64,Cost-saving,0.629266618,Cost-saving,0.224704778,Cost-saving,0.922169342,Cost-saving,0.382193767,Cost-saving,NA,Cost-saving,,,,,,,0,0,Industry